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1. Introduction 
Carcinoma of the uterine cervix is the most common type of cancer in developing countries and a 
leading cause of death from cancer among women. Worldwide it ranks 7th in frequency overall, and 
2nd in frequency among women, with an estimated 493,000 new cases and 274,000 deaths in 2002.1 
In developed countries, the incidence rates are generally low, with age-standardized rates less than 
14.5 per 100,000.1 In the Netherlands, the incidence and mortality rate declined over the last decades 
respectively from 762 in 1989 to 584 in 2003 and from 3.3 deaths per 100,000 women to 2.0 deaths 
per 100,000 women in 2003.2  
Population-based screening programmes for the prevention of cervical cancer have contributed to a 
significant decline in incidence and mortality of the most common type of cervical cancer, i.e. 
squamous cervical cancer (SCC). Cervical adenocarcinoma (AC) is less common but, despite 
screening programmes, increasing incidence especially in young women, has been reported by 
several authors.3-7 However, some reports indicate a stable or even a slightly decreasing incidence in 
AC, particular starting in the last decade.8,9  
Although cervical cytologic screening has proven its efficacy, the search for improvement is a 
continuing story. Since epidemiological and molecular studies have convincingly demonstrated that 
certain types of human papillomavirus (HPV) are etiologically involved in the development of cervical 
cancer and its precursors,10-14 incorporation of HPV tests into screening programmes might identify 
women who are at risk of developing invasive cervical cancer. Indeed, several studies have 
demonstrated the potential relevance of HPV testing in cervical cancer screening programmes and in 
the management of patients with slightly abnormal cytology.15-20 Moreover, HPV testing has already 
been implemented as an adjunct or even postulated as a substitute for cytological screening 
programmes for the prevention of cervical cancer.16,20 
Up till now, 15 HPV genotypes are identified as having oncogenic potential and classified as high-risk 
HPV (hr-HPV) genotypes.21 The most common hr-HPV types found in cervical cancer are HPV 16 and 
18.22 Interestingly, although almost 70% of the cervical carcinomas are HPV 16 and/or HPV 18 
positive, the prevalence of each genotype detected in squamous-cell carcinomas and 
adenocarcinomas of the cervix is clearly different, indicating a potential malignant tropism of HPV 16 
and 18. HPV 16 has been found in over 60% of cervical squamous-cell carcinomas and in about 20% 
of cervical adenocarcinomas. On the other hand, HPV 18, the second most frequent detected HPV 
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type in squamous-cell carcinoma (10-12%), is strongly associated with adenocarcinoma of the cervix 
given an almost 50% HPV 18 positivity.23-26 
The limited success of screening programmes in detecting glandular precursors, due to a lack of 
clinical and cytomorphologic characteristics of these lesions, basic research focusing on different 
aspects of specific HPV 18 behaviour and clinical appearance might add to the knowledge of the 
development of adenocarcinoma and its precursor lesions. Moreover, with the development of HPV 
vaccination programmes, mainly focused on HPV 16 and 18, data contributing to a more complete 
understanding of the natural history of these HPV infections, are warranted. The studies in this thesis 
are mainly directed to specific features of HPV 18. 
 
2. Glandular cervical lesions 
2.1 Glandular precursor lesions  
Global estimates indicate that cervical adenocarcinomas now constitute up to 25% of cervical cancer 
in western countries.8 
The development of cervical cancer through different premalignant stages has been known for some 
time and forms the basic principle of population-based cervical screening programmes. The purpose 
of cervical screening is to identify women at risk for cervical cancer by detecting precursor lesions in 
order to treat them before they develop into invasive cervical disease. 
After Broders had recognized carcinoma in situ as a precursor of invasive disease 27 in 1932, 
Papanicolaou and Traut demonstrated in 1941 that exfoliative cytology could be used to detect 
cervical in situ carcinoma and invasive disease.28 Almost 3 decades later, Richart assumed that 
cervical carcinoma develops from non-invasive stages, initiating the terminology of cervical 
intraepithelial neoplasia (CIN).29 CIN lesions are classified as CIN 1 (mild dysplasia), CIN 2 (moderate 
dysplasia) and CIN 3 (severe dysplasia or carcinoma in situ) on the basis of cellular and nuclear 
changes and on the thickness of the epithelium involved in neoplastic changes.30  
Although the development of squamous-cell carcinoma through the different stages of precursor 
lesions is well established, less is known about glandular precursor lesions. Parallel classification 
schemes for endocervical adenocarcinoma precursors (cervical intraepithelial glandular 
neoplasia=CIGN) have been proposed by Gloor and Hurlimann 31, including lesions with less severity 
than adenocarcinoma in situ (ACIS). On the other hand, some authors suggest, based on 
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retrospective pathological examination of neoplastic and nonneoplastic cone biopsies and 
hysterectomy specimens, that no morphologic evidence exists to support the existence of a spectrum 
of endocervical glandular changes that culminates in ACIS.32  
Celllular characteristics of endocervical intraepithelial precursor lesions have been poorly documented, 
because these lesions are relatively rare and morphologic criteria are not well defined.32,33 Yet, every 
pathologist occasionally encounters atypical glandular lesions that are not inflammatory but do not 
reach the threshold for a diagnosis of ACIS.34 Therefore, the term “atypical glandular cells of 
undetermined significance” (AGUS) was introduced at the 1988 Bethesda Conference and defined as 
“morphologic changes in glandular cells beyond those that are suggestive of a benign reactive 
process, but which are insufficient for the interpretation of ACIS”. Three years later, in the new 
Bethesda System, the term has been eliminated and redefined as “atypical glandular cells” (AGC), 
with the following subclassifications: not otherwise specified (NOS), favor neoplasia, endocervical 
ACIS, and adenocarcinoma.35 Although a definition was made, the category of AGC covers a wide 
spectrum of different diagnoses ranging from reactive changes to columnar cells from other sites of 
the female genital tract to ACIS. In conclusion, although some authors have succeeded in quantifying 
borderline atypias in the cervix, the existence of a reproducible defined entity that can be distinguished 
from adenocarcinoma in situ (ACIS) remains unproven.34,36,37 
Adenocarcinoma in situ (ACIS), however, has been described in detail and it is generally considered 
that ACIS is the precursor lesion of cervical adenocarcinoma. In 1953, Friedell and McKay were the 
first to describe ACIS and unfortunately only few subsequent investigations have been performed 
during the next 25 years.38,39 Nowadays, morphologic criteria are well established and defined for 
ACIS including nuclear hyperchromasia, nuclear enlargement, stratification and crowding.31,39,40  
It has been estimated that 12% of high-grade squamous-cell precursor lesions will, if left untreated, 
finally progress to invasive disease 41, but estimated figures for progression of ACIS to 
adenocarcinoma are lacking. 
 
2.2 Detection of cervical glandular precursor lesion 
The uterine cervix is covered with squamous and columnar epithelium (see Figure 1).The 
transformation zone forms the border between the columnar and squamous epithelium where 
metaplastic transformation of columnar epithelium into squamous epithelium occurs. 
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Due to the high cell-turnover, the transformation zone is assumed to be more susceptible to oncogenic 
influences.42 Since the first papers by Regaud and Leveuf in 1933, it is a widely discussed but 
accepted hypothesis that squamous and glandular neoplasia have a common origin and develop from 
the subcolumnar reserve cells lying in the transformation zone.33,43-47 Generally, cervical lesions are 
detected using cervical scrapes or smears (so called Pap test) of exfoliated cells from this 
transformation zone of the cervix, in order to obtain squamous cells of the ectocervix and glandular 
cells from the columnar epithelium.48 In the Netherlands, cytological diagnosis is made by using the 
KOPAC-B (in English CISOE-A) coding system.49,50 In this system five items are scored, according to 
the acronym CISOE-A, Composition, Inflammation, Squamous epithelium, Other abnormalities and 
endometrium and Endo-cervical columnar epithelium and the A stands for the adequacy of the cervical 
smear. The S, O, and E are the only parameters specifying the smear classification as used in the 
other nomenclatures concerning cytological pathology. 
 
 
Figure 1. Transformation zone of the cervix uteri 
 
Pap test sampling techniques have changed significantly over the last decades, largely with the 
addition of sampling devices developed to improve endocervical specimens. For a long time, cervical 
specimen collection depended on the use of a spatula. As adenocarcinomas arise in the endocervical 
canal, this area is not easily accessible with the spatula. Furthermore, most of the cells, lining the 
endocervical glands, are below the surface and even less accessible for sampling devices like the 
spatula. Therefore, several brush devices were launched onto the market to improve endocervical 
sampling. Moreover, several studies proposed potential benefits of improved sampling due to the use 
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of endocervical brushes and consequently better identification of precursor lesions, thus reducing 
progression to invasive disease.7,9,51-54 
Development of liquid-based cytology as an alternative for the conventional pap test is another effort 
to improve diagnostic accuracy in cervical screening programmes. In conventional smears, after 
scraping cells from the cervix, the sampling device is directly wiped on a slide and covered with a 
special designed fixative. Clustering of cells is often a problem for adequate pathologic assessment. In 
liquid-based cytology, the exam experience is similar to the conventional pap. However, once the cells 
are collected from the cervix, the sampling device is rinsed into a vial of liquid to produce a suspension 
of cells from which a monolayer of cells on a slide is prepared in the laboratory. In this way, slides can 
be reproduced and read more quickly and, the liquid sample can be used for HPV testing. However, 
recently a systematic review showed no evidence that liquid-based cytology reduced the proportion of 
unsatisfactory slides, or detected more high-grade lesions in high quality studies, than conventional 
cytology.55 Nevertheless, some countries, including the UK and the USA have already incorporated 
liquid-based cytology into screening programmes, probably because of the benefits of reproducibility 
and competence of HPV DNA testing, even long after the initial smear was conducted. 
 
3. Human Papillomavirus (HPV) 
3.1 Introduction 
Since zur Hausen initiated the concept of viral oncogenesis in the development of cervical carcinoma, 
numerous data, provided by epidemiological, clinical and molecular studies support the causal role of 
specific high-risk HPVs in the pathogenesis of cervical cancer.10-14 Human papillomaviruses are non-
enveloped, double-stranded DNA viruses of approximately 8000 base pairs. The viral genome 
consists of early and late regions containing open reading frames (ORFs), resulting in translation of 
functional proteins. The two late region open reading frames (ORFs) L1 and L2 encode two structural 
proteins composing the major and minor capsid proteins, respectively. About 15% of the viral genome, 
not encoding for proteins, plays a role in regulation of transcription and viral DNA replication. The early 
regions ORFs (E1, E2, E4-E7) are expressed early in the viral life cycle.56 Three of the early ORFs are 
the oncogenes E5, E6, and E7, modulating the transformation process. Two regulatory proteins, E1 
and E2, modulate replication and transcription. 
Chapter 1  General Introduction 
12 
Since the L1 ORF is the most conserved gene within the genome, it has together with the E6 and E7 
ORFs been used for identification of new papillomavirus types, subtypes and variants for the last two 
decades.57 In order to identify a new type, the L1, E6, and E7 ORFs should differ by more than 10% 
from the closest type known. Differences of 2-10% lead to detection of a new subtype, whereas 
differences of less than 2% need to be present in case of intratype variants.  
The HPV family consists of many different types; more than 120 types have been identified to date, of 
which 40 different types can infect the anogenital mucosa.58,59 Several HPV types, such as types 16, 
18, 31, 33 and 35, have been implicated with an etiological role in cervical carcinogenesis 60, whereas 
other types, such as types 6 and 11, are frequently detected in benign lesions such as condylomata 
acuminata. Therefore, HPV types 6 and 11 are termed low-risk (lr) HPV types and HPV types involved 
in carcinogenesis (such as types 16 and 18) are termed high-risk (hr) HPV types. 
It is generally accepted that women infected with a hr-HPV type are at higher risk of developing 
cervical cancer than those who are not infected with HPV or who are infected with one of the lr-HPV 
types.17 
 
3.2 HPV mediated carcinogenesis 
The exact role of HPV in the development of malignant disease is not fully understood but it is 
generally accepted that the physical status of the HPV genome in the host cell is of key importance.61-
64 In benign infections and in the majority of low grade cervical lesions, HPV DNA is maintained in an 
episomal (E) state, whereas HPV DNA integrated (I) into the host cell genome DNA is often found in 
high-grade pre-invasive lesions, and even more frequently in cervical carcinomas and, in cell lines 
derived from them.63,65-67 Generally, it is assumed that integration into the host chromosome leads to 
disruption of the E1 and E2 open reading frames (ORFs) of the virus. The deletion of the E2 ORF 
results in overexpression of the oncogenic E6 and E7 proteins.68 Overexpression of the E6 and E7 
gene products results in a constant suppression of key cell-cycle control proteins p53 and pRb, 
respectively, leading to genetic instability and subsequent neoplastic transformation.68,69 
 
3.3 Prevalence of HPV 
Cervical HPV infection is a common sexually transmitted infection and it has been estimated that 80% 
of women will acquire an HPV infection at some point during their life-time.70 Most women are infected 
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shortly after starting sexual intercourse.71 In women with normal cervical cytology, the estimated point 
prevalence varies from 20% in women under 25 years of age to 6% in women older than 30 years.72  
A systematic review on the role of HPV testing within a cervical cancer screening program showed 
that the hr-HPV prevalence in CIN 1 ranged from 30% to 65%, in CIN 2 from 40% to 70% and in CIN 3 
from 60 to 90%.17 Moreover, almost 100% of cervical carcinomas are hr-HPV positive.26 
In young and middle-aged women, newly acquired HPV infections are usually considered to be 
transient, at least when their duration is measured by how long the virus can be detected in cytological 
samples73,74 which, among others, depends on the detection method used.75 It is believed that the 
immune system of the host is able to clear the virus and only persistence of a type-specific hr-HPV 
infection is considered a necessary requirement in the carcinogenesis of cervical cancer.76 However, 
there is no widely accepted definition of the term persistent HPV infection, which is generally 
described as a positive HPV test on two or more occasions with a wide range of the interval period 
from 2 months to 7 years, with a median of 6 months. (see review of Woodman77)  
The mean duration of cervical HPV infection in a healthy population is thought to vary between 8.2 –
13.5 months78 but the virus might be detected intermittently and short-term fluctuations on sequential 
detection have been reported79-82 and are still under debate. Fluctuations during a single menstrual 
cycle, have not been studied in detail so far and lead to one of the studies presented in this thesis.  
 
Figure 3. HPV viewed through an electron microscope 
 
3.4 Human papillomavirus type 18 
Epidemiological studies have shown that human papillomavirus 18 is the second most common hr-
HPV type found in cervical cancer after HPV 16.83 About 70% of squamous-cell carcinoma and 86% of 
adenocarcinoma of the cervix are attributable to HPV 16 and 18.84,85 Therefore, studies conducted in 
the field of HPV vaccination in order to prevent cervical carcinoma, are mainly focused on these two 
high-risk types.  
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HPV 18 is preferentially found in adenocarcinoma in situ in 47 to 89% of cases24,84,86-89 and in cervical 
adenocarcinomas (almost 50%) whereas only 10-12% of the cervical squamous-cell carcinomas are 
HPV 18 positive.3,25,84,90,91 Moreover, recently it was shown that when comparing invasive 
adenocarcinoma cases to cytologically normal controls, the odds ratio for HPV 18 is 15.0 and for HPV 
16 only 1.3, suggesting a preferential risk of HPV 18 for adenocarcinoma.24 
Some reports postulate that, HPV 18 related lesions are more aggressive and have a poorer 
prognosis than HPV 16 lesions,92,93 due to differences in viral integration patterns of HPV 16 and 18. 
In clinical tissue samples of invasive cervical disease, HPV 18 is always present in an integrated form 
whereas HPV 16 can also be found in both integrated and episomal forms.61,94 
 
Figure 2. Schematic structure of HPV 18 
 
On the other hand, cross-sectional studies have demonstrated that HPV 18 is rarely detected in high-
grade CIN.92,95 It has been suggested that HPV 18 associated disease progresses rapidly through the 
preinvasive stages of cervical neoplasia 92, sustained by observations in mice models where HPV 18 
produced dysplastic changes in early-passage cells.92,96 However, in a study on risk factors for rapid-
onset cervical carcinoma, with a high frequency of adenocarcinomas, no significant association with 
HPV 18 was found.96,97 Furthermore, a longitudinal study on the relative risk of a cytological disorder 
after an incident exposure to HPV 18 compared to HPV 16 revealed no excess risk for high-grade 
lesions after an HPV 18 infection. Moreover, duration time from the first positive HPV test to 
acquisition of a cytological disorder was not linked to the infecting HPV type.98 
Clinical and epidemiological studies have shown that cervical cytological smears are less sensitive in 
detecting glandular precursor lesions than in detecting squamous precursor lesions.52,99,100 Because 
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HPV 18 is preferentially identified in ACIS and in cervical glandular invasive disease,3,25,84,90,91 it can 
be hypothesized that HPV 18 has a local preferential site in the endocervical canal. 
 
4. HPV detection methods 
Since HPV cannot be cultured efficiently and the clinical performance of serological assays is poor, 
diagnosis of HPV infection is based almost entirely on molecular tools.101 Accurate assessment of 
HPV infections relies on the detection of viral nucleic acid (NA).101,102 
Before the era of amplification technology, Southern blot, dot blot, filter in situ and in situ hybridization 
using HPV type-specific probes were generally used to detect and genotype HPV.103,104 
However, applicability was limited because of low sensitivity, specificity or both, or because of complex 
execution of techniques and low potential for automated implementation, which is required for 
processing a large number of clinical samples in a population-based screening design. New 
amplification techniques, such as polymerase chain reaction (PCR), nucleic acid sequence-based 
amplification and ligase chain reaction, and advances in old techniques, including liquid hybridization 
(e.g. hybrid capture)105 have revolutionized the potential of molecular screening for HPV over the past 
decades.  
In general, the HPV tests that are now widely used are based on two principles. The first involves 
hybridization of the target HPV-DNA to labelled RNA probes in situ.102,105 The Hybrid Capture 2 system 
(hc2, Digene Corp., USA; FDA approved), a non-radioactive signal amplification method, is based on 
this principle. The hc2 can only identify samples positive or negative for 13 hr-HPV types without 
genotyping and is currently commercially available, FDA approved and frequently used.  
The principle of the consensus polymerase chain reaction (PCR) assays is based on PCR 
amplification of the target HPV-DNA directed by so-called consensus or general primers that bind to 
highly conserved regions within the L1 ORF of all genital HPV genotypes. Subsequent to the 
amplification of HPV DNA, reverse hybridization of the amplicon to multiple oligonucleotides provides 
the possibility to simultaneously type up to 37 different HPV genotypes. The oligonucleotide probes 
which recognize the different genotypes are frequently tailed with poly(dT) and immobilised as parallel 
lines to membrane strips. The assays called line blot assay (LBA), line probe assay (LiPA) or linear 
array (LA) require only a small amount of PCR product. In order to detect and genotype HPV DNA in a 
single sample type-specific primers are used and multiple PCR ought to be used separately. The most 
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commonly used PCR based HPV test are the GP5+/6+ system, the recently developed target-
amplification method Roche AMPLICOR ® HPV test (Roche Molecular Systems, Inc., Branchburg,NJ, 
USA), the PGMY primer set, and the SPF10 primer set. Various reports have assessed and 
occasionally compared the various tests. Generally, the tests are reviewed to be able to rapidly 
genotype HPVs present in clinical samples with high sensitivity and specificity.101,106-109 
The sensitivity of HPV detection methods is based on the threshold value of the viral load/viral 
concentration. Amplification detection assays like PCR-based techniques, are highly sensitive (low 
threshold of viral load detection) in comparison with liquid hybridization tests (high threshold), like the 
Hybrid Capture® 2 test. Therefore, ‘analytical’ and ‘clinical’ sensitivity and specificity are introduced, in 
order to distinguish clinically irrelevant and clinically relevant HPV-positivity rates.110 Clinicians should 
be aware of the differences and be able to correctly translate HPV test results into clinical practice. 
From an epidemiological point of view, as long as the natural history of HPV infections is not fully 
understood and HPV-vaccination programmes/trials are developed and need to be accurately 
monitored, HPV tests with the highest possible analytical sensitivity are required. In that case 
analytical sensitivity will be of scientific relevance. 
 
5. Outline of this thesis  
As discussed in the previous paragraphs, cervical adenocarcinoma and its precursor lesions are a 
challenge to clinicians, colposcopic experts and pathologists. As HPV 18 is preferentially identified in 
glandular preinvasive and invasive disease, studies on specific properties of HPV 18 might gradually 
add to unravelling its natural behaviour. A more complete understanding of the natural history of HPV 
18 is important in perspective of cervical screening programmes, in follow up of vaccinated 
populations and, for clinical triage and follow-up of treated women with cervical disorders. 
In chapter 2 we describe the results of a pilot study on fluctuations in HPV prevalence during a single 
menstrual cycle. Based on the results of that study we hypothesized that there is a local preference 
site of HPV 18 in the endocervical canal. The following issues are investigated: 
 
1. Does HPV 18 appear in cytological samples taken after large loop excision of the 
transformation zone? (chapter 3) 
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2. Will cervical sampling with devices that reach deeper into the endocervical canal reveal 
more endocervical cells? If more endocervical cells are found will the detection rate of HPV 
18 be higher? (chapter 4) 
3. Is the physical status of HPV 16 in high-grade squamous and glandular lesions different 
from the physical status of HPV 18 in these cervical lesions? (chapter 5) 
As outlined in paragraph 4, different HPV detection assays are available with different sensitivity and 
specificity depending on the threshold value of viral load/concentration. PCR-based techniques are 
more sensitive than liquid hybridization techniques. General PCR assays, with a broad spectrum of 
specificity for HPV, are now widely used for the detection of HPV in clinical cervical material. Apart 
from categorising the tests based on the technique used, current tests can be divided according to 
their actual purpose, i.e. high-risk HPV detection or HPV genotyping. Tests distinguishing high-risk 
HPV infections from no HPV infection for instance could be specifically valuable for mass-screening 
purposes. However, are the results of various PCR-based techniques comparable? We addressed the 
following question: 
4. What is the concordance of a more established (SPF10-LiPA) PCR-based assay and a newly 
developed (Roche AMPLICOR) PCR-based assay, regarding high-risk HPV detection 
(chapter 6) and regarding HPV-genotyping (chapter 7)? 
The results presented in the following chapters are generally discussed in chapter 8 and summarized 
in chapter 9. 
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Summary 
In the last few years much attention has been focused on the implementation of human papillomavirus 
detection in population based screening programmes to identify women at risk for cervical cancer. 
Short-term fluctuations in prevalence of human papillomavirus were investigated within a single 
menstrual cycle. The highest prevalence was found at the follicular phase (55%), whereas the 
cumulative prevalence was 75%.  
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Introduction 
Epidemiological and molecular studies over the past two decades have convincingly demonstrated 
that certain types of human papillomavirus (HPV) are etiologically related to the development of most 
cases of cervical cancer.1-7 A systematic review on the role of HPV testing within a cervical cancer 
screening program showed that the high-risk HPV prevalence in CIN 1 ranged from 30% to 65%, in 
CIN 2 from 40% to 70% and in CIN 3 from 60 to 90%.8 Furthermore, HPV can be detected in almost 
all cervical carcinomas.7 
The estimated point-prevalences of genital HPV infections detected by PCR based methods among 
populations of women with cytological normal cervical smears range from 1.5% to 44.3%, with a 
weighted average of 16.2% and show an age-related pattern.9,10 The highest prevalences are found in 
women in their early twenties.9,11 Newly acquired genital HPV is usually transient in women with 
normal cervical cytology.12 The mean duration of cervical HPV infection in a healthy population varies 
between 8.2 –13.5 months.13,14 Short-term fluctuations of an individual’s HPV status, however, are still 
a matter of debate. Several studies have reported a fluctuating expression of HPV, probably due to 
differences in viral load, inadequate sampling or reactivation of endogenous infection.14-17 Single point 
measurements of HPV 16 in cervical smears are of limited value for assessment of an individual’s 
HPV status.15 
Before incorporation of HPV testing in screening programs for prevention of cervical cancer it is 
important to gain more insight in the actual prevalence of HPV, influenced by short-term fluctuations. 
The aim of this study was to investigate the presence of cervical HPV in the different phases of a 
single menstrual cycle in women with regular cycles. 
 
Materials and Methods 
Cervical samples for HPV detection and cytological examination were obtained from 20 women visiting 
the outpatient clinic for fertility problems at the University Medical Centre Nijmegen, the Netherlands. 
Only women with regular menstrual cycles were included. Patients with cervical treatment for 
abnormal cervical cytology in the past ten years were not included in the study. After giving informed 
consent, patients were interviewed regarding their medical history, smoking habits, use of 
contraceptives and sexual behaviour. 
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Cervical smears for HPV detection and cytological classification were obtained using the Cervex brush 
(Rovers, Oss, the Netherlands). 
On a weekly basis at four visits during their fertility screening cycle, cervical swabs were taken for HPV 
detection.  The first cervical sample was taken in the menstrual period (2nd or 3rd day of the cycle), the 
second sample between the 7th and 11th day of the cycle, the third sample around ovulation (between 
the 12th and 15th day) and the fourth sample in the luteal phase (7 days post ovulatory, 20th – 24th day). 
Ovulation was ascertained by ultrasound examination. Cytological classification was done by an 
experienced pathologist.   
Cervical scrapes were processed into AgarCyto cellblocks as described by Kerstens et al.18 HPV 
detection was assessed using a short fragment polymerase chain reaction (SPF10-PCR). HPV 
genotyping was performed via a reverse hybridization line probe assay (LiPA), capable of detecting 
and genotyping 25 different HPV types simultaneously.19,20 Statistical analysis was performed using 
the chi-square and McNemar tests, where appropriate. Values of p < 0.05 were considered to indicate 
a significant difference in HPV prevalence between different phases in the menstrual cycle. 
 
Results 
Eighty cervical smears for HPV testing were obtained from 20 women with a mean age of 33.8 ± SD 
4.9 years (range 22-43 yr.). All women except one were non-smokers. The use of oral contraceptives 
was discontinued by all, at least one year before attending our fertility clinic. The mean age of 
sexarche was 18.6ִ ± 4.5 years. Nine women had been monogamous since their sexarche, while the 
other 11 women were at least monogamous for the past 2 years. The mean frequency of sexual 
intercourse was 2.3 weekly.  
Chlamydia serum antibodies were present in four patients. Urine samples from these four women, 
obtained to test for an active chlamydia infection, were all negative.  
Three patients (15%) had a history of abnormal cervical smears. Two of them had ASCUS in 1986 
(Table I, case no.12, HPV negative) and in 1996 (Table I, case no.10, HPV 33 positive) respectively. 
The third woman (Table I, case no. 6, HPV negative) was treated in 1984 by a large loop excision of 
the transformation zone, which was histologically classified as severe dysplasia. The follow-up smears 
of this patient were normal. 
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At the end of the study 15 (75%) women appeared to be positive for HPV at least one time within one 
menstrual cycle. Single point measurements of HPV ranged from 20 to 55% (Figure 1). The 
cumulative prevalence of oncogenic HPV was 70% (14 out of 20), with point-prevalences fluctuating 
between 15 and 45% (Figure 1). 
In the follicular phase (7th -11th day) a higher rate of HPV positive samples was found compared to the 
other phases, which was significantly different according to the chi-square test  (p = 0.02).  
Fifteen different HPV genotypes were detected of which 73.3% were high-risk.  
 
0%
25%
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75%
100%
Day 2-3 Day 7-11 Day 12-15 Day 20-24 Cumulative
all HPV
hr HPV
*
 
 
Figure 1. Point-prevalences and cumulative prevalence of HPV during one  
menstrual cycle in infertile women 
 hr = high-risk. * p < 0.05  
 
Three (15%) patients harboured HPV 16 in their lower genital tract, whereas five (25%) women tested 
positive for HPV 18 for at least one time within the menstrual cycle (Table 1). Chlamydia serum 
antibodies were found positive in three women with HPV 18 in their cervices. Interestingly, HPV 18 
was only detected in the first half of the menstrual cycle and never in the luteal phase.  
Five women in the HPV positive group (33.3%) contained multiple HPV genotypes in one or more of 
their cervical smears. In one patient seven different oncogenic HPVs were detected of which type 56 
and 66 were consistently present (table 1, case no. 8). She was the youngest participant, (22 years) 
and had her first sexual experience at the age of 14 years. She was monogamous for the last 2.5 
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years, but counted at least 10 different sexual partners in the past. The cervical smear of this patient 
was cytological classified as ASCUS.  
The only other patient with ASCUS (table 1, case no. 11) was positive for HPV 16 in the luteal phase. 
The cervical smears of the other 18 women were cytologically diagnosed as normal.  
 
 HPV genotypes 
Case Day 2-3 Day 7-11 Day 12-15 Day 20-24 
1     
2     
3  18   
4  6,52 6,52 6,52 
5 33    
6     
7  18 52  
8 56,66 34,39,42,56,66 6,18,34,39,42,56,66 34,39,56,66 
9  6  6,16,52 
10  33   
11   6 16 
12     
13  18 18  
14  58   
15 18,44 18 18  
16     
17 11 11  11 
18    33 
19   31,51  
20  16   
 
Table 1. Individual point prevalences of HPV genotypes in infertile women with  
 normal cervical cytology. 
  Bold figures = high-risk HPV  
 
Discussion 
In this study, the cumulative prevalence of HPV in infertile, cytologically normal women following 
weekly consecutive cervical scrapes during one menstrual cycle was found to be 75%. To our 
knowledge this is the highest cumulative prevalence that has ever been reported for women with 
normal cervical cytology after such a short follow-up of only 4 weeks. Several other studies 
demonstrated cumulative cervical HPV prevalence in cytologically normal women of 34.7% to 
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66.7%11,14-17. However, in those studies multiple samples were taken during study periods of 10 weeks 
to 5 years in contrast to 4 weeks in our study (table 2). Moreover, we studied the prevalence of all 
HPV genotypes in contrast to Schneider (only HPV 16) and de Villiers (HPV 6, 11, 16, 18). In a group 
of Panama City prostitutes cumulative HPV prevalence amounted 82% after 8 months with at least 6 
repeated examinations.21 However, cytological classification of these women was not reported. 
In our study, point prevalence of HPV genotypes changed throughout the menstrual cycle with the 
highest prevalence in the follicular phase. From then onwards, single-point HPV prevalence decreases 
until the end of menstruation. Exfoliation of cervical cells by scraping the surface of the cervix 
consecutively every week could have led to a reduction in cells containing HPV, resulting in a lower 
prevalence of HPV with every following smear. However, the initial smears have been made at the 
menstrual period at which the lowest prevalence of HPV was found. 
Single time HPV detection rates in our study varied between 20 and 55%, which is comparable to 
earlier reports.15,16 It has been postulated that variations of the single time prevalence are due to 
differences in viral load. Viruses can be persistent but undiagnosed because of fluctuating levels of 
infection around the threshold of detectability.17  
 
Author/year Study period (months) 
Number of 
samples HPV genotype 
Cumul. HPV 
prevalence (%) 
De Villiers 1992 60 ≥ 2 6,11,16,18 34.7 
Schneider 1992 12 10 16 66.7 
Wheeler 1996 2 ≥10 all types 58.3 
Ho 1998 36 5 all types 60 
Woodman 2001 36/60 4/? all types 44/60 
Van Ham 2002 1 4 all types 75 
 
Table 2. Cumulative (cumul.) prevalence of cervical HPV in several studies in overview with  
number of samples and study period.  
? = not indicated 
 
We found a significantly higher prevalence of HPV in the follicular phase, with predominance of HPV 
18 (38.4%). Whereas others found a significantly higher prevalence of HPV in the luteal phase of the 
cycle.15 However, in this last study, women were only tested for HPV genotype 16.  Wheeler et al 
reported no significant correlation in HPV detection and phase of menstrual cycle, although the point 
prevalence of HPV in the follicular phase was higher than in the luteal phase.16 Fairley et al performed 
a study to determine if HPV detection or the size of the tampon specimen was effected by the 
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menstrual cycle. They concluded from their study that the timing of the menstrual cycle effects the size 
of tampon specimens but not the probability of detecting HPV DNA.22  
The high prevalence of HPV in the follicular phase of our study group is remarkable.  
A possible explanation for this finding is the physiological widening of the cervical canal in the follicular 
phase, resulting in the collection of more or different clinical material from the deeper layers of the 
endocervix. This could also be an explanation for the predominance of HPV 18 in the follicular phase. 
After all, in a recent study of the prevalence of HPV in cervical adenocarcinomas it was demonstrated 
that HPV 18 was the most prevalent followed by HPV 16.1  
It could be argued that fertility problems per se could have led to a population-based bias in HPV 
prevalence. However, the cervical HPV prevalence in a group of infertile women undergoing ovarian 
stimulation with gonadotrophins varied between 6.8% and 7.8 %, which was similar to 8.4% in the 
control group.23  
In women with normal cytological cervical smears, a cumulative prevalence of HPV as high as 75% in 
one menstrual cycle has never been reported. This result suggests that single point detection of HPV 
underestimates the true prevalence of HPV in a population. Sequential scrapes appear to be 
necessary to determine the true HPV status in individual cases.  
We conclude from our study that detection of HPV on single sample basis may lead to false negative 
results. These results may have important implications for population based HPV screening.  
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Summary 
Large loop excision of the cervical transformation zone (LLETZ) is a well-established treatment mode 
for high-grade cervical intraepithelial neoplasia. It has even been postulated that LLETZ is responsible 
for the elimination of the infectious agent, human papillomavirus (HPV), causing the lesion. Most 
studies on HPV detection after LLETZ have focussed on the persistence of high-risk (hr-) HPV to 
identify women at risk for residual or recurrent disease. Therefore, the appearance and significance of 
hr-HPV types newly detected after surgical treatment has not been studied extensively so far.  
The presence of hr-HPV in 85 high-grade squamous cervical LLETZ biopsies and in the first follow-up 
smear was determined. In 80 (94%) of the LLETZ biopsies hr-HPV was detected in contrast to 30 
(35%) hr-HPV positive follow-up scrapes. Twenty of the 80 hr-HPV positive women (25%) had the 
same hr-HPV genotypes in their follow-up cervical smears as was found in the corresponding 
biopsies. In the follow-up smear of 13 women a new hr-HPV genotype was detected and HPV 18 was 
newly detected in 8 of them. 
The remarkable high presence of newly detected HPV 18 genotypes may argue for a release or re-
activation of this virus from proximal layers of the cervical canal incised during surgery.   
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Introduction  
Carcinoma of the cervix is the most common type of cancer in the developing world and the leading 
cause of death from cancer among women.1 In women with cervical cancer, malignant cells usually 
develop from cytological abnormal tissue that can range from mildly dysplastic (cervical intraepithelial 
neoplasia; CIN 1) to moderately or severely dysplastic (CIN 2/3). Women with cervical abnormalities 
indicative of a human papillomavirus (HPV) infection have a much higher risk of cervical cancer than 
those with normal cytology.2,3 Virtually all cervical carcinomas are associated with an infection by one 
of the high-risk HPV genotypes.4 Studies towards the oncogenic potential of these HPV types clearly 
support a causal relationship with cervical cancer carcinogenesis.5-7 To date, over 120 distinct HPV 
genotypes have been identified. About 30 of the known HPVs, and even a higher number of variants, 
have been detected in genital mucosa. These genital HPVs can be divided subsequently into groups 
based on frequency of association with malignant tumors, and thus presumed oncogenic potential. 
Thirteen HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) are classified as high-risk 
types, directly associated with invasive cervical cancer.8 
Large loop excision of the cervical transformation zone (LLETZ) is a well-established method of 
treatment for high-grade CIN and has shown to be highly effective.9,10 It has even been suggested that 
effective surgical treatment of CIN also eliminates the HPV infection responsible for the lesion.11-13 
Most studies on HPV detection after treatment for high-grade CIN have focused on either the 
persistence of hr-HPV in general or type-specific persistence to identify women at risk for residual or 
recurrent disease.14-17 The appearance of new hr-HPV types after surgical treatment has, however, not 
been reported in detail so far. 
To obtain more insight into this phenomenon, hr-HPV detection and genotyping was performed both 
on high-grade squamous cervical biopsies from 85 women treated with a large loop excision of the 
transformation zone (LLETZ), and on the corresponding first follow-up smear taken within six months 
after treatment. 
 
Materials and Methods 
All women, visiting the outpatient colposcopy clinic of the Radboud University Nijmegen Medical 
Centre between April 1997 and October 1999 and treated for high-grade squamous cervical 
intraepithelial neoplasia with a LLETZ), were eligible for the study. A high-grade squamous cervical 
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lesion was histologically defined as CIN 2 or worse. All patients were first time referrals from the 
population-based screening programme for the prevention of cervical carcinoma. The referral cervical 
scrape indicating a high-grade lesion was performed by the general practioner and was unavailable for 
HPV assessment. The participants gave written informed consent after approval of the local ethical 
committee. The LLETZ procedures were undertaken by an experienced gynaecologic oncologist. 
The cervix and transformation zone were visualized by colposcopy. Assessment of the transformation 
zone was enhanced using a 3% acetic acid solution. If an abnormality, suggestive for CIN 2 or worse, 
was identified on the cervix immediate electrosurgical excision of the whole transformation zone would 
follow. After local infiltration of the paracervical tissue with 1 ml of 2% lidocainehydrochloride with 
epinefrine in every quadrant, an ERBE (Tubingen, Germany) electrosurgical unit was used, together 
with a wire loop of appropriate size to excise the transformation zone, as described previously.9,10 
Within 6 months after the LLETZ procedure cervical scrapes were collected using the Cervex brush® 
(Rovers Medical Devices B.V., Oss, The Netherlands) and processed using a liquid-based approach. 
An experienced pathologist, blinded for the results of the HPV test, performed histopathological and 
cytological examination.  
HPV detection was carried out on both the LLETZ biopsies and the cervical scrapes, using a broad-
spectrum short fragment polymerase chain reaction (SPF10PCR) assay as previously described.18 In 
case of a positive HPV test, subsequent HPV genotyping was performed via a reverse hybridization 
line probe assay (LiPA), allowing for simultaneous typing of all hr-HPV genotypes. The SPF10-LiPA 
assay has proven to be sensitive, specific, effortless, and reproducible in the assessment of HPV in 
cervical scrapes and histological samples, and has been clinically validated.18-21 The assay has also 
shown to be highly comparable to other frequently used primer-sets.19,21 
 
Specimen preparation 
A single 3 µm thick section of every LLETZ-biopsy specimen was put into a reaction tube and 
incubated overnight at 56ºC in 200 µL 10 mM Tris-HCl with 1 mM EDTA, 0.2% Tween-20 and 
proteinase K (0,3 mg/ml). Proteinase K was inactivated by a 10 min incubation at 100ºC for nucleic 
acid isolation. The sample was centrifuged for 10 min. at 11,000 rpm and 10 µl were directly used for 
PCR analysis.  
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The MagnaPure LC Isolation station (Roche Diagnostics GmbH, Molecular Biochemicals, Mannheim, 
Germany) was used for nucleic acid isolation of the cervical scrapes in liquid cytology media; 200 µl of 
material was isolated using the Total Nucleic Acid isolation kit (Roche Diagnostics GmbH), as 
described by the manufacturer. Nucleic acid was resuspended in a final volume of 100 µl; 10 µl were 
used for PCR analysis. A water blank control was processed with each batch of 10 samples. After 
isolation of DNA, samples were tested for the presence of HPV by the SPF10-LiPA HPV 
detection/genotyping assay.  
 
SPF10-LiPA HPV detection/genotyping 
PCR amplification of HPV DNA 
Broad-spectrum HPV DNA amplification was carried out using a short PCR fragment assay (SPF10-
LiPA detection/genotyping assay, system). This assay amplifies a 65-bp fragment of the L1 open 
reading frame, and allows detection of at least 43 different HPV types.18-20 SPF10-PCR system was 
carried out in a final reaction volume of 50 μl, containing 10 μl of the isolated DNA sample, 10 mmol/L 
Tris-HCL (pH 9.0), 50 mmol/L KCL, 2.0 mmol/L MgCl2, 0.1% Triton X-100, 0.01% gelatin, 200 μmol/L 
of each deoxynucleoside triphosphate, 15 pmol each of the forward and reverse primers tagged with 
biotin at the 5’end, and 1.5 units of AmpliTaq Gold® (Applied Biosystems, Foster City, CA). The 
mixture was incubated for 9 minutes at 94°C, 40 cycles of 30 seconds at 94°C, 45 seconds at 52°C 
and 45 seconds at 72°C, with a final extension of 5 minutes at 72°C. Appropriate negative and positive 
controls were used to monitor the performance of the PCR method in each experiment. The presence 
of HPV DNA was determined by hybridization of SPF10 amplimers to a mixture of general HPV probes 
recognizing a broad range of HPV genotypes, in a microtiter plate format, as described previously.18 
 
Hr-HPV genotyping by reverse hybridization  
The HPV-genotyping assay was performed as described previously.19 Briefly, equal volumes (10 μl 
each) of the biotinylated PCR products and denaturation solution (400 mmol/L NaOH, 10 mmol/L 
EDTA) were mixed in test troughs and incubated at room temperature for 5 minutes, after which 1 ml 
of pre-warmed (37°C) hybridization solution (3x SSC [1x SSC is 0.15 mol/L NaCl plus 0.015 mol/L 
sodium citrate], 0.1% SDS) was added, followed by the addition of one strip per trough. Hybridization 
was performed for 1 hour at 50 ± 0.5°C in a closed water bath with back-and-forth shaking. The strips 
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were then washed twice with 1 ml of wash solution (3x SSC, 0.1% SDS) at room temperature for 20 
seconds, and once at 50°C for 30 minutes. Following this stringent washing, strips were rinsed twice 
with 1 ml of a standard rinse solution. Strips were then incubated on a rotating platform with an 
alkaline phosphatase-labeled streptavidin conjugate diluted in a standard conjugate solution, at 20–
25°C for 30 minutes, after which strips were washed twice with 1 ml of rinse solution and once with 
standard substrate buffer; color development was initiated by the addition of 5-bromo-4-chloro-3-
indolylphosphate and nitroblue tetrazolium to 1 ml of substrate buffer. After 30 minutes incubation at 
room temperature, the color reaction was stopped by aspiration of the substrate buffer and addition of 
distilled water. The 28 oligonucleotide probes which recognize 25 different types (including 13 hr-HPV 
genotypes) were tailed with poly(dT) and immobilised as parallel lines to membrane strips (Labo Bio-
medical products B.V. Rijswijk, The Netherlands). The LiPA strips were manually interpreted using the 
provided reference guide. The samples that tested positive using DNA enzyme immuno assay but 
showed no results on the LiPA strip were considered to be HPV X-type, that is, genotypes not 
available on the LiPA strip.  
Every hr-HPV genotype found in the follow-up scrapes, which was not detected in the LLETZ biopsy 
was considered as a non-identical hr-HPV type and further defined as “new” HPV type. Assessment of 
hr-HPV genotypes in the follow-up samples, identical to those found in the histological specimens 
were defined as “identical” types. Statistical analysis was performed by the McNemar’s test where 
appropriate; p < 0.01 was considered as a significant difference. 
 
Results  
Ninety women, treated for a high-grade squamous cervical lesion with a LLETZ, were eligible for the 
study. In five cases no follow-up smear was performed within 6 months after treatment, therefore 
these women were excluded from the study group. The remaining 85 women had a mean age of 36 
yrs (range 26-58 yrs) and had undergone at least one follow-up smear within 6 months (range 2-6 
months) after the LLETZ procedure.  
 
High-risk HPV prevalence in the LLETZ biopsies 
In 20 cases (24%) the LLETZ biopsy showed CIN 2 on histopathological examination and 65 cases 
(76%) had CIN 3 or worse (2 cases of micro-invasive carcinoma). In 80 (94%) of the histopathological 
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specimens, at least one high-risk (hr-) HPV genotype was found. In 4 of 85 (5%) biopsies a single low-
risk (lr-) HPV type was detected and in one (1%) case no HPV DNA was detected. This HPV negative 
sample was histologically diagnosed as CIN 3. 
Multiple infections with at least one hr-HPV were present in 31 of 80 positive patients (39%), single hr-
HPV infections were found in 49 of 80 patients (61%). The most common hr-HPV genotypes (as a 
single or as part of a multiple infection) detected in the biopsy were HPV 16 (56%), followed by HPV 
31 (20%), HPV 52 (11%), HPV 33 and HPV 18 (both 9%), HPV 51 and 58 (both 8%), HPV 39, HPV 45 
and HPV 56 (all 4%). An overview is shown in Table 1. 
 
 hr-HPV genotype 
 16 18 31 33 39 45 51 52 56 58 
Single infection 28 4 4 3 1 1 3 4 1 0 
Multiple infection 17 3 12 4 2 2 3 5 2 6 
Total 
% 
45 
56.3 
7 
8.8 
16 
20 
7 
8.8 
3 
3.8 
3 
3.8 
6 
7.5 
9 
11.3 
3 
3.8 
6 
7.5 
 
Table 1. Distribution of hr-HPV types in 80 hr-HPV positive LLETZ biopsies 
 Due to multiple HPV infections, the overall percentage of hr-HPV types exceeds 100% 
 
High-risk HPV prevalence in the follow up cervical scrapes 
In 55 of 85 (65%) follow-up cervical scrapes, made after the LLETZ procedure, the hr-HPV status was 
negative. In eight of these hr-HPV negative cases, the cytological diagnosis revealed a mild disorder 
defined as atypical squamous (four cases) or glandular (three cases) cells of undetermined 
significance (ASCUS resp. ASGUS) and one case as low-grade squamous intraepithelial lesion 
(LSIL), whereas the remaining 47 cases had normal cytology . In 30 of 85 (35%) of the follow-up 
scrapes hr-HPV was detected, which is statistically lower than the 94% hr-HPV positive biopsy 
samples (McNemar’s test, p<0.01). An overview of the results is shown in Table 2. 
In 21 of these 30 hr-HPV positive cases a normal cytological result was found, whereas four cases 
showed ASCUS, two cases LSIL and three cases showed a high-grade squamous intraepithelial 
lesion (HSIL). 
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 hr-HPV genotype 
 16 18 31 33 39 45 51 52 56 58 
Single infection 7 4 0 1 1 0 1 1 1 1 
Multiple infection 5 5 3 0 0 0 1 1 0 1 
Total 
% 
12 
40 
9 
30 
3 
10 
1 
3.3 
1 
3.3 
0 
0 
2 
6.6 
2 
6.6 
1 
3.3 
2 
6.6 
 
Table 2. Distribution of hr-HPV types in 30 hr-HPV positive cervical smears after LLETZ 
 Due to multiple HPV infections, the overall percentage of hr-HPV types exceeds 100% 
 
Identical hr-HPV genotypes 
Twenty of the 80 (25%) women with a hr-HPV DNA positive biopsy showed identical hr-HPV 
genotypes in their follow-up cervical smear. In 3 of these 20 patients additional new HPV genotypes 
were detected in the follow-up scrapes (Table 3). Cytological examination of the 20 scrapes showed a 
normal result in 13 cases, ASCUS in 3 cases, LSIL in 2 cases and finally HSIL in another 2 cases. 
 
Case 
hr-HPV in 
LLETZ 
biopsies 
hr-HPV 
after 
LLETZ# 
Follow-up 
(months) 
Cytology after 
LLETZ 
1 16 18 6 normal 
2* 16 16  18 3 normal 
3 45 18 6 normal 
4 51 31 6 normal 
5 52 16 2 normal 
6 - 18 4 ASCUS 
7 16  39 18 3 normal 
8 16  52 18 3 normal 
9 16 18 4 normal 
10* 16  58 16  51 3 normal 
11 33  35 18 3 normal 
12 16  52 39 4 HSIL 
13* 31 31  52 3 normal 
 
Table 3. Thirteen cases with a new hr-HPV genotype in the first follow-up 
 smear after LLETZ 
  *not only a new hr-HPV  type but also an identical hr-HPV type was found 
   #new hr-HPV genotypes are underlined 
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New hr-HPV genotypes 
In the follow-up smear of 13 of the 85 patients (15%) a new hr-HPV type was detected, which was not 
present in the LLETZ biopsies of these patients; in 3 cases multiple hr-HPV infections and in 10 cases 
a single hr-HPV infection were found. HPV 16, HPV 31, HPV 39, HPV 51, and HPV 52 were all newly 
detected once in the follow-smears. HPV 18, on the other hand, was newly detected in 8 of these 13 
women (62%) (Table 3). Cytological examination of these 13 cases revealed a normal result in 11 
cervical scrapes, ASCUS in one scrape, and high-grade squamous intraepithelial lesion (HSIL) in one 
scrape.  
 
Discussion 
Both epidemiological and molecular studies have now clearly established that high-risk human 
papillomaviruses (hr-HPV) are the causative agents for the development of malignant lesions of the 
cervix and their precursors (CIN). Although effective therapeutic options to treat the viral infection are 
not yet available, LLETZ has shown an effective therapy for high-grade CIN lesions.9,10 Moreover, 
surgical treatment is suggested to eliminate the HPV infection causing the cervical abnormality.11-13 
This study also shows that 65% (55/85) of the women treated with LLETZ harbored no hr-HPV DNA in 
their follow-up cervical scrapes, suggesting that the surgical treatment eliminated the HPV infection. 
However, hr-HPV DNA was still detected in 30/85 follow-up scrapes (35%) taken within 6 months after 
the treatment. In 20 patients (24%) an identical hr-HPV genotype was found in both the follow-up 
scrape and the LLETZ biopsy specimen. As suggested in the literature this could reflect non-
eliminated persistent hr-HPV infections increasing the risk for residual or recurrent disease. Indeed, 
residual CIN can be detected in up to 16% of the patients after treatment of CIN. Adding hr-HPV 
detection could thus be used as a prognostic marker to identify women at risk for residual CIN.14-17 
However, hr-HPV genotypes were also detected in the follow-up scrapes of 13/85 women (15%) that 
were not detected in the preceding LLETZ biopsy. These newly detected HPV genotypes were either 
found as part of a multiple infection, containing also the same hr-HPV genotype found in the LLETZ 
biopsy (three women), or as a single new hr-HPV genotype different from the hr-HPV genotype found 
in the biopsy specimen (nine women). In one woman a new hr-HPV genotype was found in the scrape 
while the LLETZ biopsy showed no evidence of hr-HPV presence. 
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Although data on newly detected hr-HPV genotypes in women treated for high-grade CIN are rare, this 
phenomenon has been reported previously. Mann and colleagues reported a new HPV genotype in 
the cervical follow-up smear in 10% of 152 women treated for high-grade CIN after a median follow-up 
period of 12 months.13 Bollen et al even found new HPV genotypes in 19% of the follow-up smears in 
a study comprising 91 women treated with two different treatment modalities for high-grade CIN.22 
In the present study a remarkably high percentage of newly detected hr-HPV 18 was observed in 
cervical smears taken after surgical treatment; in 8 of the 13 women (62%) with new hr-HPV 
genotypes, HPV 18 DNA was detected. In the hr-HPV positive LLETZ specimens HPV 18 was 
detected in only 9%. This latter percentage is highly comparable to the 7% prevalence of HPV 18 
recently published in an extensive meta-analysis of 4338 squamous high-grade lesions.23 
How can we explain this finding? Firstly the results could be explained due to a coincidental finding 
related to the relatively small number of newly detected hr-HPVs in the follow-up cervical scrapes 
influencing the outcome of the analysis. However, as only 7 of the LLETZ biopsies were HPV 18 
positive, this explanation, although it cannot be excluded, does not seem plausible.  
Newly acquired HPV infection of the cervix by sexual intercourse after the LLETZ procedure could also 
be an explanation for the appearance of new HPV types. However, it is very unlikely that the high 
appearance rate of specifically HPV 18 could only be explained by sexual transmission, also because 
of the very low rate of HPV 18 in the LLETZ biopsies as indicated above.  
Another possible explanation for the appearance of new HPV types is that after elimination of the 
lesion, that is, the HPV-infected epithelium, other types which were not detected previously may fill the 
niche.13 In fact, many women are infected with multiple HPV genotypes and genotypes can remain 
undetectable due to differences in viral load. After eradication of the HPV types with the highest viral 
loads, HPV types with lower viral loads are no longer dominated by prominent types and will start 
shedding again 24 becoming detectable after treatment. 
But again, how does this affect the presence of specifically HPV 18? 
During the LLETZ procedure the transformation zone is excised as a result of which the proximal 
layers of the endocervical canal are incised which may result in a release or re-activation of HPV from 
these layers of the cervical canal. HPV infections detected after LLETZ may therefore represent HPV 
genotypes that are more prevalent in the proximal layers of the cervix. Interestingly, from this point of 
view, it has been clearly demonstrated that although almost 100% of the cervical carcinomas are  
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hr-HPV DNA positive 4, the prevalence of specific hr-HPV genotypes detected in squamous cell 
carcinomas and adenocarcinomas of the cervix clearly differ indicating a potential malignant tropism of 
different hr-genotypes. For example, HPV 16 is found in over 60% of cervical squamous cell 
carcinomas and in about 20% of the cervical adenocarcinomas, while, HPV 18 is detected in only 10% 
of the cervical squamous cell carcinomas but in more than 50% of the cervical adenocarcinomas.5,25-27 
As HPV 18 seems to play a more prominent role in the development of cervical adenocarcinomas 
HPV 18 may have a local preference site in the endocervical canal. After removal of the transformation 
zone of the cervix by the LLETZ procedure, certain genotypes of HPV in the proximal layers of the 
cervix, as HPV 18, may become detectable. As HPV 18 seems to play a predominant role in this 
specific histological type of cervical cancer, studies towards comparison of different cervical sampling 
devices for ectocervical cell sampling and endocervical cell sampling are warranted, to investigate its 
potential to detect HPV 18 in the proximal layers of the cervix and to determine the risk of HPV 18 
associated abnormalities. 
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Abstract 
Despite population-based screening programmes for the prevention of cervical cancer the incidence of 
cervical adenocarcinomas continues to increase. HPV 18 is preferentially found in adenocarcinomas 
and it has been suggested that the endocervix is the preference site for HPV 18. The purpose of the 
present study is to test whether a recently developed cervical sampling device (Cervex-Brush® 
Combi) results in more endocervical cell collection and therefore in a higher detection rate of HPV 18. 
Cervical samples were taken consecutively with both the traditional Cervex-Brush and the new 
Cervex-Brush Combi in one session from 49 healthy women in the first and the second half of a single 
menstrual cycle. Endocervical glandular cell amounts were evaluated and the presence of HPV was 
assessed by the SPF10-Line Blot 25 assay. 
Samples taken with the Cervex-Brush Combi contained a higher mean number of endocervical cells 
compared to samples taken with the Cervex-Brush. In the second half of the menstrual cycle, a 
significant higher cellular density of endocervical cells was found in the specimens obtained by the 
Cervex-Brush Combi. Moreover, these samples showed more HPV 18 positive cases at the second 
half of the menstrual cycle compared to samples taken with the Cervex-Brush.  
In conclusion: the Cervex-Brush Combi yields significantly more endocervical cells per sample and in 
addition results in higher detection rate of HPV 18 in the second half of the menstrual cycle. 
The new sampling device might therefore contribute to improve detection of endocervical lesions. 
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Introduction 
Cancer of the uterine cervix is the second most common cancer in women accounting for almost 10% 
of all new cancer cases worldwide.1,2 Population-based screening programmes for the prevention of 
cervical cancer have contributed to a significant decline in incidence and mortality of squamous 
cervical cancer.3,4 Although several authors have reported an increasing rate of cervical 
adenocarcinomas (AC)5-9 some reports indicate a stable or even a slightly decreasing incidence in AC, 
particularly starting in the last decade.10,11  
The purpose of cervical screening is to identify women who are at risk for cervical cancer by detecting 
precursor lesions in order to treat them before they develop into invasive cervical cancer. However, 
adenocarcinoma in situ (AIS) is relatively difficult to detect before the development of invasive disease. 
Glandular lesions originate in the endocervical canal and thorough sampling of this area can be 
difficult. It is still a diagnostic challenge for pathologists to recognize cytological characteristics which 
are associated with precursor lesions of cervical adenocarcinomas.12-14  
As infections with high-risk human papillomavirus (hr-HPV) play an essential role in the development 
of premalignant cervical lesions and cervical cancer15-20, HPV testing has been implemented as an 
adjunct or even postulated as a substitute for cytological screening programmes for the prevention of 
cervical cancer.21-23  
Up till now, over 120 distinct genotypes of HPV have been identified. About 30 of the known HPVs 
have been detected in genital mucosa. Fifteen HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68, 73, 82) have been classified as being high-risk and another 3 HPV types (26, 53, 66) as being 
probably high-risk.24 Interestingly, although almost 100% of cervical carcinomas are hr-HPV DNA 
positive20, the prevalence of specific hr-HPV genotypes detected in squamous cell carcinomas and in 
adenocarcinomas of the cervix is clearly different, indicating a potential malignant tropism of different 
hr-genotypes. For example, HPV 16 is found in over 60% of cervical squamous-cell carcinomas and in 
about 20% of the cervical adenocarcinomas. On the other hand, HPV 18 has been found in only 10-
12% of the cervical squamous cell carcinomas while over 50% of cervical adenocarcinomas are HPV 
18 positive.15,20,25,26 Adenocarcinomas in situ (AIS) have also been associated with HPV 18 in 66% to 
89% of cases. Accordingly, HPV 18 seems to play a more prominent role in the development of 
cervical adenocarcinomas than in squamous tumours of the cervix15,16,25-27, which suggests the 
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existence of a local preference site or different oncogenic potential for specific hr-HPV genotypes  in 
the upper layers of the endocervical canal.15,28,29  
Several sampling devices were especially developed to reach these upper layers of the cervical canal 
(and are usually used in combination with another device, which collects cells from the ectocervical 
surface) in order to get a specimen that is “satisfactory for cytological evaluation”. Recently the 
Rovers® Cervex-Brush® Combi (Rovers Medical devices, Oss, The Netherlands, image 1A) has been 
developed to combine collection of ectocervical cells with endocervical cells in a single sampling 
device. The Cervex-Brush Combi device is different from the conventional Rovers® Cervex-Brush® 
(image 1B) in a complete endocervical sampler, the longer middle hairs, which can make it easier to 
reach the upper layers of the endocervical canal, have been replaced. 
 
 
Image 1A. Cervex-brush Combi      Image 1B. Cervex-brush 
 
The purpose of this study is to test whether the new Cervex-Brush Combi sampling device is able to 
collect more endocervical cells and results in a higher detection rate of HPV 18 than the conventional 
Cervex-Brush. Furthermore, because several authors have reported on the influence of the menstrual 
cycle on the detection of HPV and the different genotypes of HPV 29-32, samples will be studied in 
relation to the phase of the menstrual cycle. 
 
Materials and Methods 
After approval of the local ethical committee, 49 participants, recruited from a database of volunteers 
from a commercial research company (Dinox Medical Investigations, Nijmegen, the Netherlands) were 
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included. Eligible candidates were not allowed to take any hormonal medication and menstrual cycles 
had to be on a regular 4-weeks basis.  
After written informed consent, cervical smears were prospectively taken twice during one 
spontaneous menstrual cycle. The first smears were taken between 12th and the 15th day of the cycle 
and the second smears 1 week later. Per visit, two cervical scrapes were taken of each participant 
with two different sampling devices. In order to avoid contamination of HPV from the upper layers of 
the endocervical canal to the ectocervical surface, cells were first scraped from the ectocervix with a 
Cervex-Brush, followed by a second smear with the Cervex-Brush Combi.  Specimens were then 
processed using a liquid-based approach (Thin Prep®, Cytyc Corporation, Marlborough, MA, USA) that 
provides monolayer distributions for cytological assessment and makes it possible to isolate DNA for 
HPV detection assays. HPV detection was performed on the liquid-based cervical scrapes, using a 
broad-spectrum short fragment polymerase chain reaction (SPF10 PCR) assay as described by Kleter 
et al.33 In case of a positive HPV test, subsequent HPV genotyping was performed via a reverse 
hybridization line probe assay (HPV SPF10  Line Blot 25, Labo Bio-Medical products b.v. Rijswijk, The 
Netherlands), allowing for simultaneous typing of 25 different genotypes of HPV (including 15 hr-HPV 
genotypes) as described previously.34 The HPV SPF10  Line Blot 25 assay has proven to be sensitive, 
specific, simple, and reproducible in the assessment of HPV.33-35  
Thin layer specimens were processed with the Thin Prep T3000 (Cytyc Corporation, Marlborough, MA, 
USA) and stained with the Papanicolaou method. An experienced pathologist assessed and reported 
cytological diagnosis according to the Dutch KOPAC-B system (in English CISOE-A) coding 
system.36,37 In this system five items are scored, according to the acronym CISOE-A, Composition, 
Inflammation, Squamous epithelium, Other abnormalities and endometrium, Endo-cervical columnar 
epithelium and the A stands for the adequacy of the cervical smear. The S, O, and E are the only 
parameters specifying the smear classification as used in the other nomenclatures concerning 
cytological pathology. The total number of endocervical cells in every cytological specimen was 
counted manually. Since most endocervical cells were clustered, the total number of endocervical cells 
in a specimen was estimated, using four categories: clusters of 1-25 cells; 25-50 cells; 50-100 cells 
and more than 100 endocervical cells.  
Statistical analysis was done by Chi-square, McNemar’s or Wilcoxon’s sign rank test where 
appropriate. A significance level of p ≤ 0.05 was chosen.  
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Results 
Hundred-ninety-six cervical specimens were taken from 49 women with a mean age of 26.8 ± SD 6.4 
years (range 18-44 yrs). Only 7 women were multiparous (range 1-7) and the remaining 42 were 
nulliparous. Thirty-three were non-smokers while the remaining 16 smoked 1 to 25 cigarettes a day. 
The age of sexarche ranged from 14 to 25 yrs (mean 17.6 yrs) while seven women had never had a 
sexual relationship with men. The number of sexual partners varied from 0 to over 10 male partners. 
Of 7 women who had never had sexual intercourse with a male partner, five were virgins and two had 
had only sexual contact with women. The use of condoms was consequently carried out in only one 
case and five women had never used oral contraceptives. Cytological classification was made for the 
smears obtained in the first half of the cycle and none of them showed any abnormality. 
 
 Mean number of endocervical cells 
  
mean 
 
 
 
mean difference 
 
1sthalf of menstrual cycle 
(n=49) 
   p-value* 
Cervex-Brush® 211     
Cervex-Brush® Combi 311     
   100  0.291 
2nd half of menstrual cycle 
(n=49) 
    
Cervex-Brush® 335     
Cervex-Brush® Combi 1362     
   1027  0.001 
Overall      
(n=98)      
Cervex-Brush® 273     
Cervex-Brush® Combi 837     
   564  0.001 
      
 
Table 1. Mean number of endocervical cells per Thin Prep slide for two sampling devices 
 *Wilcoxon’s sign rank test 
 
Endocervical cells 
In the first half of the menstrual cycle, the Cervex-Brush Combi specimens contained a mean number 
of 100 endocervical cells more than the Cervex-Brush samples, though the difference was not 
statistically significant. In the second half of the menstrual cycle, however, the mean number of 
Chapter 4  Endocervical cell collection and HPV 18 
 
 
54 
endocervical cells in a Thin Prep slide was significantly higher in samples taken with the Cervex-Brush 
Combi device compared to the Cervex-Brush samples (Table 1). Overall, the mean number of 
endocervical cells in specimens sampled by the Cervex-Brush Combi device was significantly higher 
in comparison with samples taken with the Cervex-Brush (Table 1). 
 
 1st half  of menstrual cycle 2nd half of menstrual cycle  
Genotype Cervex* Combi† Cervex Combi p-value 
HPV 16 5 (10%) 7 (14%) 6 (12%) 5 (10%) NS 
HPV 18 3 (6%) 2 (4%) 4 (8%) 9 (18%) NS 
HPV 31 2 (4%) 4 (8%) 6 (12%) 7 (14%) NS 
HPV 33 2 (4%) 2 (4%) 0 1 (2%) NS 
HPV 39 4 (8%) 1 (2%) 2 (4%) 1 (2%) NS 
HPV 45 4 (8%) 2 (4%) 0 1 (2%) NS 
HPV 51 1 (2%) 1 (2%) 2 (4%) 1 (2%) NS 
 
all HPV 
 
22 (45%) 
 
21 (43%) 
 
21 (43%) 
 
23 (47%) 
 
NS 
all hr-HPV 20 (41%) 18 (37%) 20 (41%) 22 (45%) NS 
 
Table 2. Overview of the most prevalent HPV genotypes and all HPV positive cases sampled with two 
different devices during a single menstrual cycle 
 *Cervex-Brush ; †Cervex-Brush Combi 
 Note 1: number of all HPV genotypes = number of all HPV positive cases 
 Note 2: due to multiple infections per case, the overall number of cases ≠ total number of HPV genotypes 
 
HPV 
Only 11 (22%) women were overall HPV negative while 38 (78%) women were HPV positive at least 
at one time-point of sampling. Among these 38 women, 37 were at least once hr-HPV positive. The 
prevalence of all HPV genotypes in cervical material sampled by the Cervex-Brush Combi in the first 
half of the menstrual cycle was 43% (hr-HPV prevalence 37%) and 45% (hr-HPV prevalence 41%) for 
the Cervex-Brush. In the second half of the menstrual cycle, the Cervex-Brush Combi showed a HPV 
prevalence of 47% (hr-HPV prevalence 45%) and the Cervex-Brush of 43% (hr-HPV prevalence 41%). 
Overall, the prevalence of all HPV genotypes assessed during a single menstrual cycle on two 
different occasions is not significantly different for the two sampling techniques.  
In the first half of the cycle 28 (57%) women and at the second half of the cycle 29 (59%) women were 
HPV positive either in one or in both specimens.  
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The number of HPV 18 positive cases was higher in the second half of the cycle compared to HPV 18 
positive cases at the first half of the cycle (Table 2). In the second half of the menstrual cycle, four 
samples obtained by the Cervex-Brush were HPV 18 positive, while nine samples obtained by the 
Cervex-Brush Combi were HPV 18 positive. These nine HPV 18 positive Cervex-Brush Combi 
specimens included the same four HPV 18 positive cases of the Cervex-Brush group.  However, the 
difference was not statistically significant. There were no significant differences in prevalence of any 
one of the other hr-HPV genotypes (Table 2).  
 
 HPV 18 p-value* 
Presence of Ecc N %  
Ecc+ (n=35) 16 45.7 0.054 
Ecc- (n=13) 2 15.4  
 
Table 3. Percentage HPV18 positive smears in 48 smears of 12 HPV 18 positive women according to 
 the presence of endocervical cells (Ecc)  
 
A total number of 12 women (2 Cervex-Brush, 10 Cervex-Brush Combi) were HPV 18 positive at least 
at one time-point of sampling. Overall, 48 (2x2x12) cervical samples were taken of these HPV 18 
positive women. Thirty-five specimens contained endocervical cells (Ecc+) whereas 13 scrapes yield 
no endocervical cells (Ecc-). In the Ecc+ group, 16 samples (45.7%) were HPV 18 positive in contrast 
with 2 (15.4%) HPV 18 positive samples in the Ecc- group (Table 3). The difference was not significant 
p=0.054 (chi-square test). 
 
Discussion 
The aim of the study was to test whether the new Cervex-Brush Combi sampling device was able to 
collect more endocervical cells and would result in higher detection rate of HPV 18 in comparison to 
the conventional Cervex-Brush. Per visit, the two different samplers were consecutively used in each 
woman, which makes each participant her own control. 
Overall, the mean number of endocervical cells per Thin Prep slide was significantly higher (more than 
twice) in samples taken with the Cervex-Brush Combi compared to the Cervex-Brush device. In 
contrast to scrapes taken in the second half of the cycle, we found no significant difference in mean 
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number of endocervical cells in cervical scrapes taken at the first half of the cycle (Table 1). This 
difference in mean number can possibly be explained by the fact that cervical mucus production 
around the ovulation might not allow the collection of large numbers of endocervical cells. 
Furthermore, exfoliation of (endo) cervical cells might be higher in the second half of the cycle 
dependent on blood-levels of estrogen and progesterone. 
Depuydt and co-workers found a two- to threefold significant increase in number of endocervical cells 
when comparing  cervical samples of 100 women collected by the Cervex-Brush  to cervical samples 
of another group of a 100 women collected by the Cervex-Brush Combi.38 Although still under debate, 
in most countries the absence of endocervical cells is no longer an indication for early repeat testing 
since women without these cells in their smears are not at increased risk for high-grade cervical  
lesions.39-41  
However, Kalir and co-workers have determined whether the location, extent of disease, and growth 
patterns of endocervical adenocarcinomas influence the ability to detect malignant cells by Pap 
smears.42 Cervical adenocarcinomas and adenocarcinomas in situ were studied and almost half of the 
cases arose higher up in the endocervical canal without involving the transformation zone (TZ). 
Therefore, sampling devices, able to collect more endocervical cells might detect more lesions arising 
above the TZ. 
The overall cumulative hr-HPV prevalence was 75%, which is in accordance with other data reported 
in literature among women with normal cervical cytology after different sampling periods using different 
techniques as well.29,30,32 In fact, a high prevalence of HPV was expected as the mean age of  the 
women was 26.8 years. It has been well established that prevalence of HPV is highest among women 
in their early twenties.43,44 
When comparing overall hr-HPV prevalence for the Cervex-Brush and the Cervex-Brush Combi no 
significant differences were found. Although several studies, including ours, showed also differences in 
HPV detection at various phases of the menstrual cycle not all the differences were statistically 
significant.29,30,32 
Depuydt and co-workers found no differences in overall HPV prevalence when comparing cervical 
samples collected by the Cervex-Brush to the Cervex-Brush Combi. They did find, however, a 
significant difference in mean viral load of hr-HPV for samples collected with the Cervex-Brush Combi 
compared to Cervex-Brush specimens and suggested that by using the Cervex-Brush Combi more 
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infected HPV cells were sampled from the transformation zone. Moreover, they found more abnormal 
papsmear results in the Cervex-Brush Combi group compared to the Cervex-Brush group.38 
We detected a higher rate of HPV 18 in samples taken at the second half of the menstrual cycle with 
the Cervex-Brush Combi compared to Cervex-Brush specimens. In 4 Cervex-Brush specimens, HPV 
18 was detected while the Cervex-Brush-Combi detected HPV 18 not only in these 4 women but in an 
additional 5 women. We found a tendency (p=0.054) towards a higher detection rate of HPV 18 in the 
second half of the menstrual cycle when cervical samples contain more endocervical cells (Ecc+). 
The results of our study point to a possible tropism of HPV 18 for endocervical cells, which are usually 
found in the upper layers of the cervical canal. It is intriguing why a higher rate of endocervical cells 
and HPV 18 was found in the second half of the menstrual cycle. As mentioned earlier, exfoliation of 
endocervical cells might be higher in the second half of the menstrual cycle, which subsequently 
results in a higher detection rate of HPV 18. Furthermore, it was shown that estrogen and 
progesterone have a positive effect on the replication of HPV 18.45 Indeed, in the second half of the 
cycle higher levels of endogenous progesterone are produced and may therefore contribute to a 
higher detection rate of HPV 18.  
Within the scope of the increasing incidence of cervical adenocarcinomas, we are challenged to 
develop effective and early detection methods for glandular lesions of the cervix. Since glandular 
lesions may arise above the transformation zone and HPV 18 plays a predominant role in the 
development of cervical adenocarcinomas and their precursors, the results of the present study may 
contribute to further improvement of detection methods. Currently, HPV testing has been implemented 
as an adjunct or even a substitute to cytological screening programmes for the prevention of cervical 
cancer in a number of countries.21,23,46 Thus it might be important considering to incorporate adequate 
sampling devices of the endocervical canal in population based screening programmes in order to 
increase the sensitivity and the detection of cervical glandular lesions. Moreover, as vaccination 
programmes of HPV 16 and 18 are launched onto the market, evaluating efficacy of vaccination of 
these specific HPV genotypes is of utmost importance. Therefore, strategies to refine detection of HPV 
18 are warranted. 
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Abstract 
Although the exact role of high-risk human papillomavirus (HPV) in the development of cervical 
carcinomas is not fully understood, there is considerable evidence that viral integration into the host 
genome could be a driving factor in the transformation of premalignant lesions into cervical 
carcinomas. 
Our aim was to analyze the physical status (episomal versus integrated) of HPV 16 and 18 in high-
grade precursor lesions of adenocarcinomas of the cervix (ACIS) in comparison to high-grade 
squamous cell lesions (CIN 3) in order to further elucidate possible differences in the etiology of these 
cervical preneoplasias. The physical status was assessed by using DNA in situ hybridization in 39 
cervical specimens comprising 30 CIN 3 lesions and 14 ACIS lesions and including 5 cases with 
coexisting ACIS/CIN 3. 
A significantly higher number of ACIS (93%) showed integrated HPV as compared to CIN 3 (37%) 
lesions (p<0.001). In particular HPV 16 was significantly more present in an integrated form in ACIS as 
compared to CIN 3. HPV 18 showed integration in nearly all CIN 3 and all ACIS lesions. In the five 
combined lesions integration of HPV 16 and 18 was found in the ACIS compartment, while in the 
squamous compartment this was only seen for HPV 18 with HPV 16 showing an episomal distribution. 
In the combined lesion showing co-infection of both HPV types, HPV 16 was found only in CIN 3 with 
an episomal as well as an integrated pattern and HPV 18 was detected exclusively in ACIS in an 
integrated form. 
We conclude that oncogenic HPV integration occurs relatively frequent in ACIS as compared to CIN 3, 
which is particularly obvious for HPV 16. This reflects intrinsic properties of endocervical cell types and 
may explain a different malignant potential of ACIS in comparison to CIN 3. 
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Introduction 
Cervical cancer is one of the most common malignant diseases in women worldwide.1 Certain types of 
human papillomaviruses (HPV) are known to be etiologically involved in the development of cervical 
cancer and its precursors.2-4 Fifteen HPV genotypes are considered high-risk HPV, with HPV 16 and 
HPV 18 being identified in about 70% of all cervical squamous cell carcinomas and in 86% of 
adenocarcinomas.4,5 The prevalence of HPV 16 and HPV 18 in squamous cell carcinomas and 
adenocarcinomas of the cervix is clearly different. HPV 16 is found in over 60% of cervical squamous 
cell carcinomas and in about 20% of cervical adenocarcinomas. In contrast, HPV 18 is found in only 
10 to 12% of the cervical squamous cell carcinomas while over 50% of cervical adenocarcinomas are 
HPV 18 positive.6-8  
The exact role of oncogenic HPV in the development of malignant disease is not fully understood but it 
is generally accepted that the physical status of the HPV genome in the host cell is of key importance 
in this respect.9-13 In the majority of low grade cervical lesions, HPV DNA is maintained in an episomal 
state, whereas integrated HPV DNA is often found in high-grade pre-invasive lesions, and even more 
frequent in cervical carcinoma.11,14-16 Generally, it is assumed that integration into the host genome 
leads to disruption of the E1 and E2 open reading frames of the virus, resulting in overexpression of 
the oncogenic E6 and E7 proteins, which leads to suppression of the cell cycle control proteins p53 
and pRb, respectively, followed by genetic instability and subsequent neoplastic transformation.17,18  
The vast majority of low-grade cervical intraepithelial neoplasia (CIN 1) lesions regress spontaneously 
and only very few of these lesions progress to high-grade neoplasia (CIN 2/3). It has been estimated 
that 12% of CIN 2/3 lesions eventually progress to invasive cervical cancer if left untreated.19 Neither 
morphologic parameters, nor the presence of HPV, or other molecular markers e.g. Ki67 or p16, can 
predict whether a high-grade CIN will progress to cervical carcinoma. Integration of high-risk HPV has 
been associated with progression of CIN to invasive carcinoma.11,13,20-22 Interestingly,  in vitro studies 
have found higher frequencies of integration of HPV 18 than for HPV 16 9,23-25, indicating a different 
malignant potential of these two HPV subtypes. Although the development of cervical squamous cell 
carcinoma through the different stages of CIN is well established, less is known about glandular 
precursor lesions. It is generally considered that ACIS is the precursor lesion of cervical 
adenocarcinomas and is categorized analogous to CIN 3.26,27 With respect to the role of HPV 16 
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and/or 18 in the etiology of the glandular and squamous lesions, conflicting data exist in the 
literature.28,29 
The aim of the present study was to assess the relation between the physical status of HPV 16 and 18 
on the one hand, and subtype of the lesion on the other, using DNA HPV in situ hybridization (ISH) in 
CIN 3 and ACIS. Next to the solitary lesions, combined ACIS/CIN3 cases were analysed to establish 
the temporary relationship between the integration process of both HPV subtypes.  
Information derived from these studies could be helpful in elucidating differences in behaviour of 
premalignant squamous cell lesions and lesions originating from endocervical cells. 
 
Methods  
Patient material 
Formalin-fixed, paraffin wax-embedded cervical biopsies, diathermic large loop excisions and cold 
knife conization samples were selected from the Department of Pathology of Radboud University 
Medical Center Nijmegen, The Netherlands and SSGOZ, Winschoten, The Netherlands. The tissue 
samples represented CIN 3 (n=25) and ACIS (n=9) and combined ACIS/CIN3 (n=5). From each block 
a series of 4 micrometer thick sections were cut for the respective assays. The first and the last slide 
was H&E stained to insure that representative premalignant epithelium was present. Biopsies with CIN 
3 adjacent to microinvasive carcinoma were excluded since in these cases HPV 16 was integrated in 
CIN 3 regions in virtually all cases as described before.11 
 
PCR HPV detection 
HPV detection was performed using a broad-spectrum short fragment polymerase chain reaction 
(SPF10 PCR) assay as described by Kleter et al.30 In case of a positive HPV test, subsequent HPV 
genotyping was performed via a reverse hybridization line probe assay (HPV SPF10 Line Blot 25, Labo 
Bio-Medical products b.v. Rijswijk, The Netherlands), allowing for simultaneous typing of 25 different 
genotypes of HPV (including 15 hr-HPV genotypes) as described previously.30  
 
(F)ISH HPV detection 
The physical status of the virus was assessed by means of the in situ hybridization. Non-isotopic in 
situ hybridization (nISH) methods were used to distinguish episomal and integrated HPV 16 and 18 on 
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the basis of specific ISH patterns characterized by either a diffuse pattern throughout the nucleus for 
episomal HPV, a punctate pattern for integrated HPV or a mixed pattern for a mixed physical status of 
the virus.  
The digoxigenin-labelled HPV 16 or 18 probes were obtained from PanPath (Amsterdam, The 
Netherlands). Two separate pretreatment procedures were used to assess the physical status of the 
virus: the mild and the harsh pretreatment methods.31 The mild pretreatment targeted episomal and 
integrated DNA as well as viral RNA. The harsh protocol, which extracts cytoplasmic and nuclear 
proteins as well as RNA and episomal DNA, was used to assess integrated HPV. The probe and 
target DNA were denatured simultaneously and hybridized overnight at 37˚C. After stringent 
posthybridization washes, the specimens were visualized using the tyramide signal amplification (TSA) 
procedure using rhodamine (TRITC)-labelled tyramide for a fluorescence ISH or diaminobenzidine 
(DAB) for brightfield microscopical detection.32 Evaluation of the HPV signals was performed 
according to the criteria described previously.31,33,34 Cases were categorized depending on the signal 
pattern of viral DNA as follows: diffuse pattern resembles episomal (E) form, punctate pattern 
resembles integrated (I) form and both patterns resemble Mixed (E+I) form. Integrated and mixed 
patterns were clustered for statistical analysis. Association between HPV status and histology were 
assessed in contingency tables and statistically analysed using the Fisher exact test. A significance 
level of p ≤ 0.05 was chosen. 
 
Results 
ACIS and CIN 3 as solitary lesions 
DNA in situ hybridization was performed on 39 cervical specimens that included 5 cases with ACIS 
lesions coexisting with CIN 3 (combined lesions).  
Statistical analysis was thus performed on a total number of 44 high-grade cervical lesions, containing 
30 CIN 3 (23 HPV 16 positive and 7 HPV 18 positive) and 14 ACIS (6 HPV 16 positive and 8 HPV 18 
positive) (see Table 1). 
Overall, episomal HPV was found in 63% of CIN 3 lesions and in 7% of ACIS lesions. HPV was 
significantly more often present in an integrated form in ACIS  lesions (93%) when compared to CIN 
3(37%) lesions (p < 0.001, Table 1)Figures 1A and B show typical examples of a mixed (episomal and 
integrated) form in different cells and a lesion exhibiting only episomal HPV, respectively. 
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Statistical analysis revealed that integrated HPV 16 occurs significantly more frequent in ACIS (83%) 
lesions compared to CIN 3 (22%) lesions (p=0.01). HPV 18 was integrated in 86% of the CIN 3 lesions 
and in all ACIS lesions (no significant difference, p=0.467). In CIN 3 lesions, integrated HPV 18 was 
significantly more frequent than integrated HPV 16 (p=0.0045) whereas no significant difference was 
found in frequency of integration between HPV 16 and 18 in ACIS lesions. Typical examples are 
depicted in figures 1E, G-I). 
 
HPV status CIN 3 ACIS total 
Overall n % n % N  
                  Episomal 19 63 1 7 20  
                  Integrated 7 23 11 79 18  
                  Mixed  4 14 2 14 6  
Total 30  14  44  
 
HPV 16  n % n %  
                   Episomal 18 78 1 17 19 
                   Integrated 2 9 3 50 5 
                   Mixed  3 13 2 33 5 
Total 23  6  29 
 
HPV 18  n % n %  
                   Episomal 1 14 0 0 1 
                   Integrated 5 72 8 100 13 
                   Mixed  1 14 0 0 1 
Total 7  8  15 
 
Table 1.Physical status of HPV 16 and/or 18 in CIN 3 and ACIS lesions 
 
Combined ACIS/CIN 3 
In both the PCR and the ISH assay (Table 2) two combined ACIS/CIN 3 lesions were only HPV 16 
positive (case 1 and 2), two were only HPV 18 positive (case 3 and 4) and one (case 5) was positive 
for both HPV genotypes. As a surrogate marker for HPV 16/18, immunodetection of p16 was applied 
to all these five cases (see for example figure 1C and F) Figures 1D and E show a HPV 16 positive 
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combined lesion, in which the CIN 3 lesion presented exclusively with episomal HPV, while in the 
ACIS an evident integrated pattern of HPV 16 is recognized.  
In both HPV 18 positive combined lesions, the virus was present in an integrated form in the ACIS part 
as well as in the CIN 3 part of the lesion.  
In the combined ACIS/CIN 3 lesion, with a co-infection of HPV 16 and 18, the ISH patterns revealed 
that in the CIN 3 part of the lesion HPV 16 was present in a mixed form (figure 1H and I). HPV 18 was 
only detected in the ACIS compartment, where it showed an exclusively integrated pattern (figure 1G). 
 
  ACIS CIN 3 
case HPV type HPV 16 HPV 18 HPV 16 HPV 18 
1 16 integrated - episomal - 
2 16 mixed - episomal - 
3 18 - integrated  - integrated  
4 18 - integrated  - integrated  
5 16/18 - integrated mixed - 
 
Table 2.Physical status of HPV 16 and/or 18 in five combined CIN 3/ACIS lesions 
 –: no HPV 16 or 18 detected 
 
Discussion 
In this study we investigated the physical status (episomal versus integrated) of HPV 16 and 18 in 
ACIS, CIN 3 and lesions containing both components side by side. Our aim was to gain a better 
understanding of the spatio-temporal relationship of the integration process of these two HPV 
subtypes and to see whether or not the observed patterns are related to the clinical behaviour of these 
high-grade cervical lesions.  
While the role of HPV in the development of squamous-cell carcinoma through the different stages of 
CIN is well established, less is known about glandular precursor lesions. Parallel classification 
schemes for endocervical adenocarcinoma precursors have been proposed by Gloor and Hurlimann 
including lesions preceding ACIS, but these endocervical glandular dysplasias are relatively rare and 
morphologic criteria are not well defined.35-37 Nevertheless, ACIS, has been described in detail and is 
generally considered to be the precursor lesion of cervical adenocarcinoma which seems to justify its  
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Figure 1. Typical examples of diffuse and punctate ISH patterns indicating  
                episomal and integrated HPV. 
 
A) A combined pattern of episomal HPV 16 (left side) and integrated HPV 16 (right side) in fluorescent ISH. DNA is counter 
stained with DAPI. B) Episomal HPV 16 detection by means of brightfield microscopy depicting replicating virus in differentiating 
dysplastic epithelium. C) p16 staining of a combined high-grade glandular (ACIS) and squamous lesion (CIN 3). D) Hematoxylin 
staining of an ACIS adjacent to a CIN 3. E) ISH depicting episomal virus in the CIN 3 lesion and integration in the ACIS 
component shown in C. F) p16 staining of a combined ACIS (left) and CIN 3 (right). G) Integrated HPV 18 in the ACIS. H and I) 
Episomal HPV and integrated HPV 16, respectively, in the CIN 3 part of the lesion shown in F. 
 
classification as being analogous to CIN 3 as the high-grade precursor in squamous cell 
carcinoma.26,27 Integration of viral DNA into the host genome in squamous lesions has been 
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postulated as a possible driving factor in the transition of high-grade intraepithelial lesion to invasive 
disease. Dysplastic lesions containing HPV in an episomal form are thought to pursue a less 
aggressive course and may not progress at all.11,13,20-22 For squamous cell carcinoma  precursor 
lesions, it has been estimated that only a minority of CIN 3 (10-20%) will finally progress to invasive 
disease when left untreated.19 
In the present study, we show that the proportion of cells with HPV DNA integrated into the host cell 
genome is significantly higher in cervical glandular lesions (93%) than in squamous cell lesions (37%), 
which is particularly obvious for HPV 16. If the natural course of ACIS lesions is comparable to that of 
CIN 3 with integrated HPV, most ACIS lesions will progress to adenocarcinomas and only a minority 
will regress. Unfortunately, data on estimated rates for progression of ACIS to adenocarcinomas are 
not available to sustain this hypothesis at this moment.  
It is not clear why the frequency of integrated viral DNA, especially HPV 16, in ACIS is significantly 
higher than in CIN 3. Preferential integration patterns of specific HPV genotypes in glandular 
progenitor cells could explain this phenomenon. After all, different cervical epithelia show a type-
specific preference to viral infection as demonstrated by epidemiological studies.6-8 HPV 16 seems to 
have the highest affinity for cervical squamous cells, while HPV 18 seems to have the highest affinity 
for the glandular epithelium.6-8 Cellular factors such as integrins and other adhesion molecules may 
play an important role in determining this differential susceptibility for HPV subtypes.38,39 Our results 
show no significant difference in integration patterns for HPV 16 compared to HPV 18 in ACIS. In CIN 
3, though, HPV 16 was less frequently integrated in the host cell genome. It can be speculated that 
epithelial preference for type specific HPV 16 or 18 infections exists, and that early after HPV infection 
of endocervical columnar epithelium, integration occurs in some cells, which then imposes a strong 
selective pressure. Hypothetically, unknown cellular factors, typical for endocervical cells might be 
responsible for an enhanced integration process and as a result for the selective outgrow of these 
cells. 
Another explanation for the high frequency of HPV integration in ACIS lesions might be found in the 
architecture of the glandular tissue, comprising only a single layer of differentiated cells covering the 
basely located reserve cells. Infection by HPV is thought to occur through microwounds of the  
epithelium that expose cells in the basal layer to viral entry.40 Viral replication is only possible in 
differentiating epithelium and thus in high-grade CIN lesions viral replication is abolished because of a 
Chapter 5  HPV integration in ACIS and CIN 3  
 70
diminished degree of differentiation of the host cells.41 Glandular epithelium consists of a single 
differentiated cell layer in which viral replication is not possible and therefore integration of the virus 
might already occur in the basal cell layer.  
The fact that HPV 16 is more frequently integrated in ACIS lesions as compared to CIN 3 is 
convincingly illustrated in the two HPV 16 positive combined ACIS/CIN 3 lesions, where HPV 16 is 
present in an integrated form in the ACIS and in an episomal form in the CIN 3 compartment (figure 
1E). This finding suggests that integration of HPV 16 depends on the cell type and that, the ACIS 
component will most likely progress more rapidly to a cervical malignant state than CIN 3 lesions. On 
the contrary, HPV 18 is nearly always present in an integrated form in both CIN 3 and ACIS lesions. 
This result is not surprising as many authors have reported on the preferentially integrated form of 
HPV 18, regardless of cell type.9, 23-25  
Some reports postulate that, HPV 18 related lesions are more aggressive  and have a poorer 
prognosis because of rapid progression through the preinvasive stages.42,43 This is  sustained by 
observations in mice models where HPV 18 produced dysplastic changes in early-passage cells 44, 
which has been linked to integration of HPV DNA into the host genome.43 Interestingly, in the present 
study, no significant difference was found in frequency of integration between HPV 16 and 18 in ACIS 
lesions, which might suggest an equal risk for both HPV types for progressing into cervical 
adenocarcinomas.  
The question remains however, whether or not the high frequency of integration in ACIS will result in 
an enhanced malignant behaviour. It has been estimated, that the average time for ACIS to progress 
to invasive disease is substantially shorter than for CIN 3 to progress to squamous cell carcinoma.45 
Moreover, in a study on risk factors for rapid-onset cervical cancer it was shown that compared to 
normal-onset cervical cancer, rapid-onset cases were significantly more likely to be diagnosed with 
adenocarcinomas or adenosquamous carcinomas, supporting the notion that in general glandular 
tumors are more aggressive than the more commonly diagnosed squamous tumors.46  
In conclusion, a definitive explanation for the observed high frequency of integration in ACIS 
compared to CIN 3 remains to be elucidated. As the integration of viral DNA into the host genome in 
ACIS lesions seems to be HPV-type independent, possible explanations may be sought in the cell 
type itself or in the histological properties of the endocervical cells.  
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Abstract 
Certain high-risk (hr) human papillomavirus (HPV) types are a necessary cause for the development 
of cervical disorders. Women with persistent hr-HPV infections have an increased risk of developing 
high-grade cervical lesions, compared with those who have no or low-risk HPV infections. Therefore, 
implementation of HPV detection into cervical screening programs might identify women at risk of 
cervical cancer. Several HPV detection methods with different sensitivities and specificities are 
available. Recently, a new PCR-based technique, the Roche AMPLICOR® HPV Test, was developed. 
This test recognizes a group of 13 hr-HPV types simultaneously. This study was undertaken to 
validate and compare HPV detection in 573 cervical scrapes, by the AMPLICOR HPV Test and the 
INNO-LiPA HPV detection/genotyping assay (SPF10-LiPA system version 1). Human β-globin was not 
detected in nine specimens, which were therefore excluded from the comparison. Eleven scrapes 
containing HPV type 53 or 66 were also excluded from the comparison because these (probably) hr-
HPV types can not be detected by the AMPLICOR HPV Test. The results of HPV detection by the 
Roche AMPLICOR® HPV Test  were confirmed by INNO-LiPA HPV detection/genotyping assay in 
539/553 cases, showing an absolute agreement of 97.5 % with a Cohen’s kappa of 0.9327, indicating 
almost complete similarity of the two tests. Like the INNO-LiPA HPV detection/genotyping assay, the 
AMPLICOR HPV Test was sensitive, specific, feasible and easy to handle. The value of the Roche 
AMPLICOR® HPV Test with a broad spectrum hr-HPV detection has to be determined in prospective 
clinical studies. 
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Introduction 
Cancer of the uterine cervix is a major cause of death. Although screening programs to identify 
precursor lesions of cervical cancer have contributed to a reduction in mortality and morbidity due to 
this disease, 500,000 new cases of invasive cervical cancer are diagnosed annually, and 230,000 
women die because of this disease.1 In developing countries, cancer of the cervix is the most frequent 
female malignancy and is responsible for about 24% of all cancers in women. In developed countries, 
cervical cancer accounts for 7% of all female cancers.1 
The human papillomavirus (HPV) family consists of many different types; more than 100 types have 
been identified to date, of which 40 types have been detected in the anogenital mucosa.2-4 Several 
HPV types, such as types 16, 18, 31, 33, and 35, have been implicated as sexually transmitted agents 
with an etiological role in cervical carcinogenesis 5, whereas other types, such as types 6 and 11, are 
frequently detected in benign lesions such as condylomata accuminata. Therefore, HPV types 6 and 
11 are termed low-risk (lr) HPV types, and HPV types involved in carcinogenesis (such as types 16 
and 18) are termed high-risk (hr) HPV types.5 
Infection by hr HPV types has been demonstrated in almost 100% of cervical carcinomas.6 Studies of 
the oncogenic potential of these HPV types have clearly demonstrated that hr HPVs are a necessary 
cause for the development of cervical cancer.7-11 
It is generally accepted that women infected with an hr HPV type are thus at higher risk of developing 
cervical cancer than those who are not infected with HPV or who are infected with one of the lr HPV 
types.12-14 Incorporation of HPV tests into screening programs might identify women who are at risk of 
developing invasive cervical cancer. Indeed, several studies have demonstrated the potential 
relevance of HPV testing in cervical cancer screening programs and the management of patients with 
slight abnormal cytology.6,11,12,15-18 Furthermore, the absence of hr HPV in cervical smears would 
permit less aggressive management of women with mild or equivocal cytological abnormalities 
because they are unlikely to progress.19-21 The importance of HPV in the genesis of cervical neoplasm 
suggests that diagnosis of a specific HPV infection would dictate a particular clinical outcome and 
hence be useful in patient management. Because of the large number of both hr and lr anogenital 
HPV types, which are all able to induce cervical disorders, the detection and typing of a broad 
spectrum of different HPV types are mandatory, certainly in the phase in which the definitive 
progression markers have yet to be established. 
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Since HPV cannot be cultured efficiently and the clinical performance of serological assays is poor, 
diagnosis of HPV infection is almost entirely based on molecular tools.22 Before the era of 
amplification technology, Southern blot, dot blot, filter in situ and in situ hybridization using HPV type-
specific probes were generally used to detect and genotype HPV.23-25 However, applicability was 
limited because of low sensitivity, low specificity, or both, or because of complex execution of 
techniques and low potential for automated implementation, which is required for processing a large 
number of clinical samples in a population-based screening design. New amplification techniques, 
such as polymerase chain reaction (PCR), nucleic acid sequence-based amplification and ligase chain 
reaction, and advances in old techniques, including liquid hybridization (e.g. hybrid capture)17, have 
revolutionized the potential of molecular screening for HPV in the past decade. 
General detection assays, with a broad spectrum of specificity for HPV, are now widely used for the 
detection of HPV in clinical cervical material15,26-28, although the Hybrid Capture 2 assay (Digene) is 
the only commercially available HPV screening test on the market. The Hybrid Capture 2 assay for 
HPV DNA detection is a liquid-based hybridization assay capable of detecting 13 hr HPV genotypes 
simultaneously.29 In 2003, a newly developed PCR-based technique, the Roche AMPLICOR® HPV 
Test, was launched. This test is also capable of detecting 13 hr HPV types, with simultaneous 
assessment of the presence of the human β-globin gene as a positive control. This test could, in 
principle, be used for screening purposes. However, no data are currently available on the 
performance and value of the assay in a clinical setting. 
The purpose of this study was to examine the utility of the AMPLICOR HPV Test, by comparing results 
with those obtained using the INNO-LiPA HPV detection/ genotyping assay. The INNO-LiPA HPV 
detection/genotyping assay is capable of detecting and genotyping 25 different HPV types 
simultaneously, and has proved to be sensitive, specific, simple and rapid in the assessment of 
HPV.22,30 A total of 573 anonymous cervical samples, were tested by both assays, and the results 
were compared. 
 
Materials and Methods 
Cervical scrapes were obtained from 573 women seeing a gynecologist for routine cervical screening. 
Specimens were collected using the Cervexbrush (Rovers, Oss, The Netherlands), and processed 
using a liquid-based (Cytyc®) approach that provides monolayer distributions for cytological 
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assessment and the possibility of isolating DNA for HPV detection assays. This method has received 
approval for clinical use from the U.S. Food and Drug Administration.31,32 Cytological classification was 
performed by an experienced cytopathologist.  
 
Specimen preparation 
For isolation of nucleic acid from cervical scrape specimens in liquid cytology medium, the MagnaPure 
LC Isolation station (Roche Applied Science) was used; 200 µl of material was isolated using the Total 
Nucleic Acid isolation kit (Roche Applied Science), as described by the manufacturer. Nucleic acid was 
resuspended in a final volume of 100 µl; 10 µl was used for PCR analysis. 
After isolation of DNA, samples were tested for the presence of HPV by the INNO-LiPA HPV 
detection/genotyping assay and the Roche AMPLICOR HPV Test. All HPV tests were performed by 
investigators unaware of the cytological status or the results of the comparative HPV detection test. 
 
INNO-LiPA HPV detection and genotyping  
(i) PCR amplification of HPV DNA 
Broad-spectrum HPV DNA amplification was performed using a short PCR fragment assay (INNO-
LiPA HPV detection/genotyping assay, SPF10 system version 1, manufactured by Labo Biomedical 
Products bv, Rijswijk, The Netherlands). This assay amplifies a 65-bp fragment of the L1 open reading 
frame, and allows detection of at least 43 different HPV types. SPF10 PCR system was performed with 
a final reaction volume of 50 μl, containing 10 μl of the isolated DNA sample, 10 mmol/L Tris-HCL (pH 
9.0), 50 mmol/L KCL, 2.0 mmol/L MgCl2, 0.1% Triton X-100, 0.01% gelatine, 200 μmol/L of each 
deoxynucleoside triphosphate, 15 pmol each of the forward and reverse primers tagged with biotin at 
the 5’end, and 1.5 U of AmpliTaq Gold® (Perkin Elmer). The mixture was incubated for 9 min at 94°C, 
40 cycles of 45 s at 45°C and 40 cycles of 45 s at 72°C, with a final extension of 5 min at 72°C. Each 
experiment was performed with separate positive and negative PCR controls.  
The presence of HPV DNA was determined by hybridization of SPF10 amplimers to a mixture of 
general HPV probes recognizing a broad range of HPV genotypes, in a microtiter plate format, as 
described previously.33 
(ii) HPV genotyping by reverse hybridization using the INNO-LiPA HPV genotyping system  
A poly(dT) tail was enzymatically added to the 3’ end of each of 25 oligonucleotides specific for 25 
different types, namely types 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 
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58, 59, 66, 68/73, 70 and 74. The tailed probes were applied as horizontal lines to membrane strips 
(manufactured by Labo Biomedical Products bv Rijswijk, The Netherlands). The HPV- genotyping 
assay was performed as described previously.22 Briefly, equal volumes (10 μl each) of the biotinylated 
PCR products and denaturation solution (400 mmol/L NaOH, 10 mmol/L EDTA) were mixed in test 
troughs and incubated at room temperature for 5 min, after which 1 ml of pre-warmed (37°C) 
hybridization solution (3x SSC [1x SSC is 0.15 mol/L NaCl plus 0.015 mol/L sodium citrate], 0.1% 
sodium dodecyl sulfate) was added, followed by the addition of one strip per trough. Hybridization was 
performed for 1 h at 50 ± 0.5°C in a closed water bath with back-and-forth shaking. The strips were 
then washed twice with 1 ml of wash solution (3x SSC, 0.1% sodium dodecyl sulfate) at room 
temperature for 20 s, and once at 50°C for 30 min. Following this stringent washing, strips were rinsed 
twice with 1 ml of a standard rinse solution.22 Strips were then incubated on a rotating platform with an 
alkaline phosphatase-labeled streptavidin conjugate diluted in a standard conjugate solution, at 20–
25°C for 30 min, after which strips were washed twice with 1 ml of rinse solution and once with 
standard substrate buffer; color development was initiated by the addition of 5-bromo-4-chloro-3-
indolylphosphate and nitroblue tetrazolium to 1 ml of substrate buffer. After 30 min of incubation at 
room temperature, the color reaction was stopped by aspiration of the substrate buffer and addition of 
distilled water. After drying, the strips were visually interpreted using a grid. 
 
 SPF10-LiPA- positive SPF10-LiPA- negative Total 
AMPLICOR HPV- positive 132 5 137 
AMPLICOR HPV- negative 9 407 416 
Total 141 412 553 
Table 1. Overview of the 553 samples tested by the AMPLICOR HPV Test and  SPF10-LiPA (only for 
 hr-HPV genotypes) 
 Absolute agreement: 97.5% 
 Kappa = 0.9327 (CI: 0.8980 – 0.9675) 
 
AMPLICOR HPV Test  
The AMPLICOR HPV Test utilizes amplification of target DNA by PCR followed by nucleic acid 
hybridization for the detection of 13 hr HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 
68. 
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PCR amplification of HPV DNA 
The AMPLICOR HPV Test amplifies a sequence of nucleotides within the polymorphic L1 region of the 
HPV genome that is approximately 165 bp in length. A pool of 12 HPV primers present in the ‘master 
mix’ (components comprise nucleotides, enzyme cofactor, Taq  DNA polymerase, AmpErase® enzyme 
[Applied Biosystems], buffers and primers) is designed to amplify DNA from 13 hr HPV types. Capture 
probe sequences are located in polymorphic regions of L1 bound by these primers. An additional 
primer pair targets the human ß-globin gene (268-bp amplicon) to provide a control for cell adequacy. 
PCR was performed with a final reaction volume of 100 µl, containing 50 µl AMPLICOR HPV master 
mix and 10 µl of the isolated DNA. The mixture was incubated for 2 min at 50°C and 9 min at 95°C, 
followed by 40 cycles of 30 s at 95°C, 45 s at 54°C and 30 s at 72°C, with a final extension at 72°C for 
at least 10 min to a maximum of 1 h. 
Hybridization 
After amplification, 100 µl of AMPLICOR denaturation solution was added to each PCR tube, followed 
by incubation for 10 min at room temperature to allow complete denaturation. Two separate 96-
microwell plates were used for detection of amplified HPV and β-globin. AMPLICOR hybridization 
buffer (100 µl) was added to each well of both plates; 25 µl of denatured amplified sample was then 
added to the appropriate wells of each detection plate. The plates were covered and incubated for 1 h 
at 37°C to allow the amplicons to bind to the oligonucleotide probes.  
Detection 
The plates were washed five times with AMPLICOR wash buffer using a BioTek MWP washer to 
remove unhybridized material. AMPLICOR avidin-horseradish peroxidase conjugate (100 µl) was 
pipetted into the wells, and the plates were covered and incubated for 15 min at 37°C. The plates were 
again washed as described above. A 100µl aliquot of AMPLICOR substrate, containing 
tetramethylbenzidine and hydrogen peroxide, was added to each well, and plates were incubated in 
the dark at room temperature for 10 min to allow color development. AMPLICOR stop reagent (100 µl) 
was pipetted into the wells and the optical density of the reaction was measured at 450 nm in a Biotek  
MWP autoreader. An absorbance reading of greater than 0.2 was considered positive for the presence 
of HPV and ß-globin. 
Agreement was measured by absolute agreement, as well as Cohen’s kappa statistics, a measure of 
the agreement between two methods that is in excess of that due to chance. 
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Cytology No. 
hr-HPV 
positive 
 
16 18 31 33 35 39 45 51 52 56 58 59 68 Double Triple Multiple 
                      
Normal 469 19% 18 4 4 2 1 4 2 4 7 3 2 3 1 26 5 2 
ASCUS∗ 30 63% 5 2 1 1 1 1   3     3 1 1 
Mild/moderate 
 dysplasia 27 67% 6 1 2  1   1 2     3 2  
Severe dysplasia 6 83% 1   1    1 1     1   
No diagnosis 7 29%         1                 1     
Total 539                  
 
Table 2. Concordant HPV detection and typing in relation to the cytological classification for both PCR tests 
 ∗
ASCUS: Atypical squamous cells of undetermined significance 
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Results 
A total of 573 cervical samples were available for the comparison. In 9/573 samples (1.5%), the 
human ß-globin gene did not test positive by the AMPLICOR HPV Test, and these samples were 
therefore excluded from the comparison.  
After HPV detection by both tests, the INNO-LiPA genotyping was performed in order to compare the 
two test results. HPV genotyping was performed on the positive samples. As the INNO-LiPA HPV 
detection/genotyping assay detects hr HPV types, lr HPV types and HPV X individually, in contrast to 
the AMPLICOR HPV Test, which detects only 13 hr HPV types as a group, the samples testing 
positive for lr HPV DNA or HPV X by the INNO-LiPA HPV genotyping assay were considered negative 
in the comparison (55 samples). Of these 55 samples, 21 samples contained lr HPV DNA and 34 
samples contained HPV X. In 51 of these 55 samples the cytological result was normal, whereas two 
samples were cytologically diagnosed as very mild dysplasia (later termed as atypical squamous cells 
of undetermined significance [ASCUS]), one scrape specimen was diagnosed as mild dysplasia and 
for one scrape specimen no diagnosis could be assessed. In four patients HPV 6 was detected, in one 
patient HPV 42 was detected, in five patients HPV 44 was detected, in three patients HPV 54 was 
detected, in one patient HPV 70 was detected, in three patients HPV 74 and in four patients double 
infection with lr HPV types were detected.  
Although HPV 53 and HPV 66 are considered probable carcinogenic5, these genotypes are not 
included in the AMPLICOR HPV Test and were therefore excluded from the direct comparison 
although HPV 53 was found by INNO-LiPA HPV genotyping in seven patients with a normal 
cytological result and HPV 66 was found in three patients with a normal cytological result and in one 
patient with a normal smear result both types 53 and 66 were detected. So the final comparison was 
made for 553 cervical samples. 
High-risk HPV DNA was detected by both the AMPLICOR HPV Test and the INNO-LiPA HPV 
genotyping assay in 132/553 cervical samples (24%). A total of 407/553 cervical samples tested 
negative for HPV DNA in both tests (74%). Therefore, both tests showed corroborative results for hr 
HPV types in 539/553 samples (Table 1 and Table 2), demonstrating a concordance of 97.5 % and κ = 
0.9327 (confidence interval, 0.8980 to 0.9675). 
The relationship between concordant HPV detection for both tests in relation to cytological 
classification is shown in Table 2. High-risk HPV DNA was detected by both methods in 88/469 
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scrapes (19%) from women diagnosed with a normal cytological classification. HPV positivity 
increased with the severity of the cytological diagnosis: hr HPV DNA was detected in 63% (19/30) of 
women with ASCUS, 67% (18/27) of women with mild to moderate disorders and 83% (5/6) of women 
 
 SPF10-LiPA test 
 
AMPLICOR HPV 
Test 
1 HPV X Positive 
2 Types 11, 18, 39, 68 Negative 
3 Type 33 Negative∗ 
4 Type 6 Positive 
5 Types 31, 70 Negative 
6 Negative Positive 
7 Type 33 Negative∗∗ 
8 HPV X Positive 
9 Types 11, 42, 51, 52, 53 Negative 
10 Types 52, 74 Negative 
11 Type 51 Negative 
12 Type 52 Negative 
13 Type 51 Negative 
14 HPV X Positive 
 
Table 3. Overview of the discordant cases 
 
* cytological diagnosis: ASCUS 
** cytological diagnosis: mild/moderate dysplasia 
 
with severe dysplasia. HPV DNA was detected in 29% (2/7) of women in whom cytological results 
could not be ascertained, due to sampling errors. A single hr HPV infection was detected by INNO-
LiPA HPV detection/genotyping assay in 87/132 HPV-positive scrapes (66%). HPV types 16, 18, 31, 
33, 51 and 52 accounted for 77% of the single HPV infections, with HPV type 16 being the most 
common (accounting for 34% of all single infections). In total, 45/132 positive cervical scrape 
specimens (34%) contained two or more HPV types (Table 1). Multiple (i.e. two or more) infections as 
a proportion of total infections were seen in all cytological classifications (normal, 38%, ASCUS, 17%, 
mild/moderate dysplasia, 19%, severe dysplasia, 17%, no diagnosis, 14%). The distribution of the 
individual HPV types within the multiple infections showed no statistically significant difference 
between the different cytological classifications, probably due to the unequal numbers in each group. 
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Since the AMPLICOR HPV Test only determines positivity, multiple infections could not be assessed 
by this method. 
In 14 cases (2.5%), the HPV test results were discordant, as shown in Table 3. The AMPLICOR HPV 
Test detected hr HPV DNA in five cervical scrape specimens in which the INNO-LiPA HPV genotyping 
assay was either negative (one case), positive for lr HPV (one case) or positive but where the type 
could not be determined (HPV X). In nine cases the AMPLICOR test results were negative, whereas 
the SPF10 LiPA detected hr HPV types in these nine cases. HPV 18 and 31 were both missed in one 
case, HPV 33 was missed twice and HPV 51 as well as HPV 52 was missed in three cases by the 
AMPLICOR. Twelve cervical scrape specimens in the discordant group were cytological diagnosed as 
normal; one smear was classified as ASCUS and the other as mild/moderate dysplasia. 
 
Discussion 
Infections with hr HPV are now considered, beyond reasonable doubt, to be a necessary cause of the 
development of cervical cancer.34,35 Women with persistent cervical hr HPV infections have a 100- to 
300-fold increased risk of developing a high-grade cervical intraepithelial lesion (CIN 3).6,14,36-39 
Although the sensitivity of hr HPV detection for identifying women with high-grade cervical 
intraepithelial neoplasia (CIN) or cervical cancer appears to be higher than that of conventional 
cytology, especially in women with borderline and mild dysplastic smear results, its clinical specificity 
is lower.21,29,40 Large randomized controlled trials are currently being conducted to investigate whether 
the addition of hr HPV detection to conventional cytology may improve the effectiveness of organized 
cervical cancer screening programs.16,41 Identification of hr HPV types may identify women with an 
increased risk of cervical disease, and may therefore provide additional clinical value.12 Indeed, in the 
United States, the American College of Obstetrics and Gynecology and the American Cancer Society 
both approved that women over 30 years old should be screened with an HPV DNA test combined 
with a cytological examination. 
If HPV testing is to be introduced into cervical cancer prevention programs, then standardized, reliable 
and accurate HPV tests are warranted.42 The newly developed, PCR-based AMPLICOR HPV Test 
may fulfil these demands. However, the test should be evaluated in a clinical laboratory setting. In this 
study, we compared HPV status in cervical scrapes using the AMPLICOR HPV Test and the INNO-
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LiPA HPV detection/genotyping assay. Both systems appeared to be highly concordant, with a kappa 
of 0.9235, demonstrating highly similar outcomes.  
In nine cases, no human β-globin was detected, suggesting an inadequacy of cellular material, 
probably due to sampling errors. In 14/553 cervical scrapes (2.1%), no agreement was found; of 
these, 5 were INNO-LiPA negative/AMPLICOR positive and 9 samples were SPF10-LiPA 
positive/AMPLICOR negative. HPV 33 was missed twice and HPV 51 and HPV 52 were missed in 
three cases by the AMPLICOR Test. Although these HPV types were identified by both HPV tests in 
the majority of the positive cases (see Table 2), these three HPV genotypes need to be watched 
carefully as additional studies are performed in the field. 
The sensitivity of HPV detection methods is based on the threshold value of the viral load/viral 
concentration. Amplification detection assays, such as PCR-based techniques, are highly sensitive 
(low threshold of viral load detection), in comparison with liquid hybridization tests (high threshold), for 
example the Digene Hybrid Capture 2 test. Snijders et al. have defined ‘analytical’ and ‘clinical’ 
sensitivity and specificity, in order to distinguish clinically irrelevant and clinically relevant HPV-
positivity rates.43 Analytical sensitivity is defined as the proportion of HPV-positive women who are 
correctly identified by a given test (but clinically unimportant), whereas clinical sensitivity identifies the 
proportion of women with disease (i.e. women with ≥ CIN 3) who are correctly identified by a positive 
HPV test. However, it must be remembered that HPV infection indicates a risk of having or developing 
a cervical lesion, and is not equivalent to a morphological disorder. Though the natural history of HPV 
infections is not fully understood, viral load is probably low during the first phase of infection but may 
increase over time, in parallel with the development of cytological disorders.44 Therefore, sensitive 
methods to diagnose HPV infection may be required in order to realize a maximum negative predictive 
value for the development of HPV-associated cervical carcinoma, particularly since most cervical 
smears are classified as normal or ASCUS. New insights in the viral load threshold, however, may 
direct the future management of hr HPV positive women, since high viral loads seems to be indicative 
for viral persistence and disease development while a low viral load is associated with clearance of an 
infection and even regression of cervical lesions, as had been reviewed recently.43 
Most current HPV screening protocols identify the presence of one of a pool of hr HPV types but do 
not identify the individual genotype or determine whether repeated positive tests are due to the 
persistence of one particular type; women who are infected with any hr HPV type are treated in the 
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same way. On the other hand, Wallin and co-workers have found a strong concordance between the 
type of HPV found in the baseline smear, before the development of cervical carcinoma, and the HPV 
type found in the biopsy specimen of the invasive cancer 39, indicating that neoplasia is associated 
with HPV-type-specific persistence. Therefore, future management of patients with neoplasia will 
probably not only include HPV detection but HPV genotyping as well.  
It should also be considered that both the Hybrid Capture 2 and the AMPLICOR HPV Test do not 
detect HPV 26, -53, -66, -73 and -82, HPV types that have been classified as probable high-risk 
(26,53, 66) or high-risk (73,82) types in a large epidemiological study of the oncogenic potential of 
HPV genotypes.5 In our comparison, we would have missed 11 of 564 (1.9%) infections in women who 
were found positive for either HPV 53 or HPV 66 by the SPF10-LiPA test. Obviously, as indicated 
above, these women would not all have developed cervical lesions or cancer, but Munoz et al., found 
1.1% of the cervical cancers positive for either one of these five types.5 
It is clear that the application of HPV testing in cervical screening programs will require further 
improvements in, and standardization of, testing methods.42 At present, consensus guidelines on 
primary screening and/or the triage of women with mild cytological disorders are lacking because of 
conflicting data in the existing literature about the prevalence of HPV in women with normal, mild or 
equivocal cytological abnormalities. The estimated point prevalence of genital HPV infections among 
populations of women with normal cytological smears ranges from 1.5% to 55% 45,46, and shows an 
age-related pattern.47 These differences in the prevalence of HPV are not only dependent on the 
screened population, but also on the clinical sample size, menstrual cycle, viral load and detection 
method used for HPV assessment. Incorporation of HPV detection and typing in primary screening 
and/or triage of cytological disorders warrants consensus guidelines and the use of highly concordant 
HPV detection methods. Whether the AMPLICOR HPV Test fulfils these demands should be further 
evaluated in further (prospective) clinical studies. 
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Abstract  
The need for accurate genotyping of human papillomavirus (HPV) infections is becoming increasingly 
important, since (i) the oncogenic potential among the high-risk HPV genotypes varies in the 
pathogenesis of cervical cancer, (ii) monitoring multivalent HPV vaccines is essential to investigate the 
efficiency of the vaccines, and (iii) genotyping is crucial in epidemiologic studies evaluating HPV 
infections worldwide. Various genotyping assays have been developed to meet this demand. 
Comparison of different studies that use various HPV genotyping tests is possible only after a 
performance assessment of the different assays. In the present study the SPF10 LiPA version 1 and 
the recently launched Roche Linear Array HPV genotyping assays are compared. A total of 573 liquid-
based cytology samples were tested for the presence of HPV by a DNA enzyme immunoassay; 210 
were found to be positive for HPV DNA and were evaluated using both genotyping assays (163 with 
normal cytology, 22 with atypical squamous cells of undetermined significance (ASCUS), 20 with 
mild/moderate dysplasia, and 5 with severe dysplasia). Comparison analysis was limited to the HPV 
genotype probes common to both assays. Of the 160 samples used for comparison analysis 129 
(80.6%) showed absolute agreement between the assays (concordant), 18 (11.2%) showed 
correspondence for some but not all genotypes detected on both strips (compatible), and the 
remaining 13 (8.2%) samples did not show any similarity between the tests (discordant). The overall 
intertest comparison agreement for all individually detectable genotypes was considered very good (κ-
value, 0.79). The genotyping assays were therefore highly comparable and reproducible.  
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Introduction 
Molecular and epidemiologic studies have shown that a persistent infection with high-risk human 
papillomavirus (hr-HPV) is the most important risk factor for both cervical cancer and its precursors.1-4 
Approximately 40 different HPV types can infect the mucosa of the anogenital tract. Based on their 
carcinogenicities these anogenital HPV types have been subdivided into low-risk HPV (lr-HPV) types, 
probable high-risk types and high-risk (hr) HPV types5, although some controversy remains regarding 
the probable high-risk genotypes.6 Almost all squamous cell cervical cancers worldwide harbour hr-
HPV types.7 Moreover, high-risk HPV DNA can be detected in 74% of the pre-malignant low-grade 
cervical intra-epithelial neoplasia (CIN) and approximately 84% of the high-grade CIN lesions.8 
Consequently, the efficacy of population based screening programmes solely using cervical cytology 
could benefit from adding hr-HPV testing.9 Accordingly, many ongoing international research projects 
assess the feasibility of introducing hr-HPV tests in the available routine screening. 
For these screening purposes, several tests have been developed in order to distinguish high-risk 
HPV infections from no HPV infection. Amongst those are the signal amplification method Hybrid 
Capture 2 (hc2, Digene Corp., Gaithsburg, Maryland, USA) and the recently developed target 
amplification method Roche AMPLICOR® HPV Test (Roche Molecular Systems, Inc., Branchburg, NJ, 
USA).10 Although both tests are commercially available and Conformité Européenne (CE) marked, hc2 
is currently the only FDA registered HPV screening assay.11 Both tests differentiate between an 
infection with one or more of 13 hr-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
68), and no hr-HPV infection; a “hr-HPV plus/minus” screening. Although these tests are not designed 
to detect the recently described probable hr-HPV, or any lr-HPV infections, some cross-reactivity 
outside of the spectrum of 13 hr-HPV genotypes has been reported for the hc2 assay.12 Neither hc2 
nor AMPLICOR HPV assays allow identification of specific genotypes13 nor do they have the ability to 
identify infections involving multiple genotypes. 
However, recent studies have provided evidence for a difference in oncogenic potential between the 
different hr-HPVs14, arguing for the importance of HPV genotyping in addition to the “hr-HPV 
plus/minus” screening. Outside of the clinical setting, HPV genotyping is a key-characteristic of studies 
evaluating the epidemiology of HPV infections worldwide. Although a number of HPV genotyping 
assays have been used in such studies a reliable comparison between the diagnostic and 
epidemiological data generated is difficult, since data on the inter-test comparisons between the 
different genotyping assays are limited. 
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The SPF10-INNO-LiPA assay is capable of amplifying up to 43 different genotypes and providing type-
specific genotype information for 25 different HPV genotypes simultaneously, has been extensively 
tested, and has proven to be highly sensitive and specific.8,15 The Roche Linear Array (LA) HPV 
Genotyping Test (Roche Molecular Systems, Inc., Branchburg, NJ, USA) is a recently launched new 
HPV genotyping assay able to genotype 37 HPV types, concurrently assessing human ß-globin. The 
full spectrum of HPV genotypes amplified by the PGMY primer system16 used in the Roche Linear 
Array HPV Genotyping Test has not been assessed beyond the probed 37 genotypes. In essence, 
both assays could be used for genotyping analysis. 
This study was designed to compare these two well-known and commonly used commercially 
available genotyping assays with HPV DNA positive samples.  
 
Materials and Methods 
Cervical scrapes were obtained from 573 women attending the Department of gynaecology for routine 
cervical screening. Specimens were collected using the Cervex-Brush® (Rovers Medical Devices B.V., 
Oss, The Netherlands) and processed using a liquid-based cytology medium (ThinPrep®, Cytyc Corp., 
Marlborough, MA, USA) that provides monolayer distribution for cytological assessment. Moreover, it 
offers the opportunity to isolate DNA for various HPV detection assays. This method has received U.S. 
FDA approval for clinical use.17,18  
 
Specimen preparation 
For isolation of DNA from cervical scrapes in liquid based cytology medium, the MagNAPure LC 
Isolation station (Roche Diagnostics GmbH, Roche Applied Science, Mannheim, Germany) was used; 
200 µL of material was isolated using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche 
Diagnostics GmbH, Roche Molecular Biochemicals, Mannheim, Germany), as described by the 
manufacturer. With each set of 28 cervical scrape samples 4 negative controls (distilled water) were 
used to monitor the DNA isolation procedure and to assess contamination. Nucleic acid was 
resuspended in a final volume of 50 µL; 10 µL were used for each of the various PCR analyses.  
 
SPF10-INNO LiPA HPV detection and genotyping (DNA enzyme immunoassay [DEIA] and LiPA) 
(i) PCR amplification of HPV DNA 
Broad-spectrum HPV DNA amplification was performed using a short PCR fragment assay (SPF10 
HPV PCR, Labo Bio-medical products B.V. Rijswijk, The Netherlands). This assay amplifies a 65-bp 
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fragment of the L1 open reading frame, and allows detection of at least 43 different HPV types.8, 19 
SPF10 PCR system was used in a final reaction volume of 50 μL, containing 10 μL of the isolated DNA 
sample and 40 μL PCR mix, which contained 10 mmol/L Tris-HCL (pH 9.0), 50 mmol/L KCL, 2.0 
mmol/L MgCl2, 0.1% Triton X-100, 0.01% gelatin, 200 μmol/L of each desoxynucleoside triphosphate 
(dATP, dCTP, dGTP, and dTTP), 15 pmol each of the forward and reverse primers tagged with biotin 
at the 5’ end, and 1.5 units of AmpliTaq Gold® (Applied Biosystems, Foster City, CA, USA). Activation 
of AmpliTaq Gold for 9 minutes at 94°C, was followed by 40 cycles of 30 s at 94°C, 45 s at 52°C and 
45 s at 72°C, with a final extension of 5 minutes at 72°C. Appropriate negative and positive controls 
were used to monitor the performance of the PCR method in each experiment.  
(ii) HPV detection by DEIA 
The presence of HPV DNA was determined by hybridization of SPF10 amplimers to a mixture of 
general HPV probes recognizing a broad range of high-risk, low-risk and possible high-risk HPV 
genotypes in a microtiter plate format, as described previously.8,15 All HPV DNA-positive samples (by 
SPF10 DEIA) were genotyped using the INNO-LiPA HPV genotyping assays and the Roche LINEAR 
ARRAY® HPV Genotyping Test as described below. Twenty randomly selected DEIA-negative 
samples that had previously been tested negative by Roche AMPLICOR HPV Test 10 were also 
assessed using both genotyping assays.  
(iii) HPV genotyping by reverse hybridization using the INNO-LiPA HPV genotyping system  
The 28 oligonucleotide probes that recognize 25 different types (see table 1) were tailed with poly(dT) 
and immobilised as parallel lines to membrane strips (Labo Bio-medical products B.V. Rijswijk, The 
Netherlands). The HPV genotyping assay was performed as described previously.15 The LiPA strips 
were manually interpreted using the reference guide provided. The samples that tested positive using 
the DNA Enzyme Immuno Assay but showed no results on the LiPA strip were considered to be HPV 
X-type, i.e., genotypes not available on the LiPA strip. 
 
Linear Array HPV Genotyping Test 
The Linear Array (LA) HPV Genotyping Test (Roche Molecular Systems, Inc., Branchburg, NJ, USA) 
is a new qualitative in vitro test for the determination of 37 anogenital HPV DNA genotypes (table 1). 
The LA test was applied to all samples that tested positive for HPV by DEIA and to 20 randomly 
selected DEIA-negative samples.  
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         Detected ina: Oncogenic 
Potential5 
HPV 
Genotype SPF10-LiPA LA 
16 X X 
18 X X 
31 X X 
33 X X 
35 X X 
39 X X 
45 X X 
51 X X 
52 X X 
56 X X 
58 X X 
59 X X 
68 Xb X 
73 Xb X 
               
High-risk 
82  X 
26  X 
53c X X Probable high-
risk 
66 X X 
6 X X 
11 X X 
34 X  
40 X X 
42 X X 
43 X  
44 X  
54 X X 
55  X 
61  X 
62  X 
64  X 
67  X 
69  X 
70 X X 
71  X 
72  X 
74 X  
81  X 
83  X 
84  X 
IS39  X 
                          
Low-risk 
CP6108  X 
    
 
Table I. Distribution of HPV-genotypes in the LiPA and LA assays 
 
 aX: detected; LiPA: SPF10-INNO-LiPA test; LA: Roche Linear Array HPV Genotyping test; 
 bLiPA does not distinguish between HPV 68 and HPV 73, since both types are detected  
by a single probe; concogenic potential of HPV 53 is controversial.6 
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 (i) PCR amplification of HPV DNA 
The LA test uses biotinylated PGMY primers to amplify a 450-basepair fragment within the 
polymorphic L1 region of the HPV genome. The PGMY amplification system has been described 
previously.16 The PGMY primers are present in the ‘master mixture’ (containing: buffer, nucleotides 
[dATP, dCTP, dGTP, and dUTP], MgCl2, and <0.02% AmpliTaq® Gold DNA polymerase) and amplify 
HPV DNA from 37 HPV genotypes including 13 high-risk types (Table I). Amplicons incorporate dUTP, 
allowing the use of AmpErase® enzyme (urasil N-Glycosylase) which is included in the master mixture 
to prevent PCR carryover contaminations. Capture probe sequences are located in polymorphic 
regions of L1 bound by these primers. An additional primer pair targets the human ß-globin gene (268 
bp amplicon) to provide a control for cell adequacy, extraction and amplification.  
PCR was performed in a final reaction volume of 100 µL, containing 50 µL HPV master mixture, 40 µL 
PCR water and 10 µL isolated DNA. The mixture was incubated for 2 minutes at 50°C and 9 minutes 
at 95°C, followed by 40 cycles of 30 seconds at 95°C, 1 minute at 55°C and 1 minute at 72°C, with a 
final extension at 72°C lasting from 10 minutes to a maximum of 1 hour. The provided HPV positive 
and negative controls were used with each set of 10 samples to assess the performance of the 
reaction.  
(ii) Hybridization and Detection 
Following amplification, the HPV and human ß-globin amplicons were denatured by immediately 
adding 100 µL denaturation solution to each PCR tube. Hybridization and HPV genotyping were 
performed as described by the manufacture (Roche Molecular Systems, Inc., Branchburg, NJ, USA). 
The strips were manually interpreted using the Linear Array HPV Reference Guide, by reading the 
individual types down the length of the strip. Samples that were both SPF10-DEIA and LA-ß-globin 
positive, yet were not reactive to any of the genotype probes on the LA strip, were considered “LA 
negative”. 
 
Design of the study  
Previously the samples had been assessed in an analysis comparing only high-risk HPV types 
detected by the Roche AMPLICOR HPV test and the INNO-LiPA HPV detection and genotyping 
assay.10 Since the present study compares two genotyping assays, only the DEIA HPV positive 
samples and 20 randomly selected DEIA (and Roche AMPLICOR) HPV negative samples were 
assessed. In order to have the most accurate comparison between the two genotyping tests, only the 
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HPV genotypes identified by both assays (i.e. lr-HPV 6, 11, 40, 42, 54, and 70; possible hr-HPV 53 
and 66; hr-HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) were considered for direct 
comparison of the individual HPV genotypes (Table I). These will be termed assay-common 
genotypes. High-risk HPV genotypes 68 and 73 were not taken into account for individual comparison, 
since these types are identified by a single probe in the LiPA assay and can thus not be distinguished. 
Moreover, the classification of HPV 53 as possible high-risk is currently disputed. When comparing the 
two genotyping assays, results were termed concordant, compatible or discordant, based on the 
following definitions. If the analyses yielded identical assay-common genotypes in both tests the 
results were termed concordant. Results were termed compatible if one or more additional assay-
common genotypes were not detected by either one of the assays. Genotyping results were termed 
discordant if there were no similarities in the assay-common genotypes between the two tests. Assay 
results for HPV genotypes uniquely identified by each of these two assays (i.e. assay-unique HPV 
genotypes 34, 43, 44, and 74 only detected by the LiPA and the assay-unique HPV genotypes 26, 55, 
61, 62, 64, 67, 69, 71, 72, 81, 82, 83, 84, IS39, and CP6108 solely detected by the LA) were not 
considered in determining concordant, compatible, or discordant status. 
From all compatible and discordant samples a re-extracted DNA sample was randomly retested in a 
blinded approach in a discrepancy analysis using both genotyping assays. Eleven concordant 
samples (6 single infections, 4 double and 1 triple infections) and six double negative (i.e. DEIA-
positive, LiPA X-type and LA negative) samples were used as positive and negative controls for both 
inter- and intra-assay performance control. All HPV tests were performed by investigators unaware of 
the results of the comparative HPV detection or genotyping tests. 
 
 
SPF10-LiPA 
 
LA result  LiPA X-type 
Assay-unique 
genotype 
Total  
Negative 9 7 16 
Assay-unique genotype 24 0 24 
Total 33 7 40 
   
Table II.Distribution of 40 excluded samples that either showed only assay-unique  
 genotypes or were HPV DNA positive but genotype negative (i.e. LiPA X-type) 
 
  X-type: HPV DNA positive sample (DEIA) without results on LiPA strip 
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Statistics  
All data were analyzed using SPSS version 12.0.1. for Windows. Agreement was measured by 
absolute agreement and Cohen’s kappa statistics, a measure of the agreement between two methods 
that is in excess of that due to chance. 
 
Results 
In total, 218 of the 573 DNA samples tested positive by SPF10 DEIA. These were considered suitable 
for analysis using the SPF10 LiPA and the LA HPV Genotyping assays. Eight samples were excluded 
from further analysis: 4 showed negative β-globin results in the LA test and from 4 other samples 
insufficient material was available to perform adequate assessment. Twenty randomly selected DEIA 
negative control samples were negative in both genotyping assays and were thus not taken into 
consideration for further analysis. Of the 210 DEIA positive samples 163 (77.6%) indicated normal 
cytology. Atypical Squamous Cells of Undetermined Significance (ASCUS) were detected in 22 
samples (10.5%), mild/moderate dysplasia was observed in 20 samples (9.5%), and 5 samples (2.4%) 
showed severe dysplasia.  
Of the 210 DEIA-positive samples tested using both genotyping assays, 40 samples were excluded 
since either one of the tests was negative whereas the comparative test detected an assay-unique 
genotype or LA was negative and LiPA showed an X-type (Table II). 
 
Assay-unique 
genotypes 
Concordant 
(No.) 
Compatible 
(No.) 
Discordant 
(No.) 
Total 
None 87 24 21 132 
LiPA 3 0 0 3 
LA 20 12 1 33 
LiPA and LA 2 0 0 2 
Total 112 36 22 170 
 
 Table III. Overview of the 170 included samples with assay-common genotypes 
 
In 132 of the remaining 170 samples, all detected genotypes that could have been identified by both 
assays. Of these samples harbouring only assay-common genotypes, 87/132 (65.9%) were 
concordant, 24 (18.2%) were compatible, and 21 (15.9%) showed discordant results (Table III). 
Finally, in 38 cases, assay-unique genotypes were detected in addition to assay-common genotypes. 
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Of these samples 25 (65.8%) had concordant results, 12 (31.6%) were compatible and one (2.6%) 
was discordant. In the final analysis of 170 samples these 38 samples were retained. The additional 
assay-unique genotypes found in these 38 samples were not taken into consideration. The outcome of 
the concordant, compatible, and discordant cases is described in detail below.  
 
No. of specific genotypes not detected 
Compatible samples Discordant samples Oncogenic potential Genotype LiPA LA LiPA LA 
16 7   1 
18 2 1   
31 2 2   
33 1   2 
35    1 
39 3    
45 2  1  
51  1  4 
52 1 1  2 
56  3 1 1 
58 3    
59 5    
High-risk 
68/73 1 1  2 
53  1 1 3 Probable high-
risk 66 1   2 
6    2 
11 1 2   
42 4  1  Low  risk 
54 8  2 1 
 Total 41 12 6 21 
 
Table IV. Overview of the 36 compatible and 22 discordant samples 
 
Concordant cases 
Of the 112 concordant cases (25 with and 87 without assay-unique genotypes) 69 (61.6%) contained 
a single HPV genotype and the remaining 43 samples contained multiple genotypes. Thirty-two 
samples (28.6%) harboured two different genotypes, 8 samples (7.1%) contained 3 HPV genotypes, 
and 3 samples (2.7%) contained 4 genotypes. One or more high-risk genotypes were detected in 
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86.6% (97/112) of these samples, whereas 7 samples (6.3%) only contained low-risk genotypes and 8 
samples (7.1%) also harboured probable hr-HPV genotypes.  
 
Compatible cases 
All 36 compatible cases were multiple infections. The LiPA assay did not detect a total of 41 
genotypes in 30 separate clinical samples. In 23 cases, 1 type was missed; in 5 cases, 2 types were 
missed; and in 2 cases, 4 types (13 low-risk, 1 possible high-risk and 27 high-risk genotypes were not 
detected by the LiPA test). The Linear ARRAY assay on the other hand did not detect 12 genotypes in 
8 separate samples. In 6 cases, 1 type was missed; in 1 case, 2 types; and in 1 case, 4 types (2 low-
risk, 1 possible high-risk and 9 high-risk HPV types). Table IV gives an overview of the individual types 
not detected. Fifteen of the 16 cases in which LiPA missed an hr-HPV type were multiple hr-HPV 
infections and tested positive for another high-risk type which was also detected in the LA.  
 
Discordant samples  
In 22 (12.9%) of the 170 samples considered, no similarity was observed in the genotypes found in the 
two tests. These were predominantly single infections. An overview of the individual discordant cases 
is given in Table IV. Twenty-seven genotypes were discrepant between the two assays in 22 different 
samples. The LA test did not detect 13 hr-HPV, 5 probable hr-HPV and 3 lr-HPV types that were found 
to be positive in the LiPA assay. The LiPA assay on the other hand failed to detect 2 high-risk, 1 
probable high-risk and 3 low-risk types, which were all found positive on the LA strip.  
The genotypes which were detectable by both assays of all 170 samples (112 concordant, 36 
compatible and 22 discordant) were individually compared as summarized in Table V. The overall 
strength of agreement between the two assays for the individual genotypes was considered good (κ = 
0.792). Although HPV 16 was detected in 45 samples using the LA test and in 39 samples using the 
LiPA agreement between the tests was considered very good with a κ-value of 0.874. The agreement 
between the two assays for the other high-risk and probable high-risk genotypes varied between 
“good” and “very good”. The agreement between the two tests for the low-risk genotypes was 
“moderate” to “perfect”. The agreement for HPV 54 was moderate since LiPA and LA shared 8 
samples harbouring the low-risk genotype whereas LA detected it in 10 additional samples. Also, the 
agreement for lr-HPVs 11 and 42 was moderate, while HPV 70 was detected in equal amounts by 
both assays. Low-risk HPV 40 was not detected in either one of the test, thus no agreement could be 
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calculated. The difference in detection of lr-HPV 54 was statistically significant (p<0.05; McNemar’s 
test). Although the differences for hr-HPV 16, 51 and 59, and lr-HPV 42 between the assays were 
large, they were considered not quite statistically significant (p>0.07 McNemar’s test). In the individual 
comparison of the other genotypes no statistically significant differences were detected.  
 
No. of genotypes found positive 
by: 
Oncogenic 
potential 
Genotype 
LiPA LA LiPA/LA 
κ-value (95% CI)b p-value 
16 39 45 38 0.874 (0.788-0.959)* 0.08 
18 14 15 13 0.887 (0.760-1.014)* 1.00 
31 13 13 11 0.833 (0.672-0.995)* 0.62 
33 10 9 8 0.833 (0.645-1.020)* 1.00 
35 9 8 8 0.938 (0.817-1.059)* 1.00 
39 7 9 7 0.869 (0.687-1.050)* 0.48 
45 5 8 5 0.761 (0.492-1.029)$ 0.25 
51 16 11 11 0.799 (0.626-0.973)$ 0.07 
52 23 21 20 0.896 (0.795-0.997)* 0.62 
56 12 9 8 0.747 (0.528-0.965)$ 0.37 
58 8 11 8 0.833 (0.646-1.020)* 0.25 
High-risk  
59 6 11 6 0.692 (0.426-0.958)$ 0.07 
53 20 17 16 0.848 (0.718-0.979)* 0.37 Probable 
high-risk 66 9 8 7 0.814 (0.606-1.023)* 1.00 
6 11 9 9 0.894 (0.748-1.040)* 0.48 
11 4 3 2 0.563 (0.072-1.053)+ 1.00 
40 0 0 0   
42 2 7 2 0.434(-0.055-0.923)+ 0.07 
54 9 18 8 0.562 (0.311-0.812)+ 0.02 
Low-risk 
70 6 6 6 1.000 (1.000-1.000)**  
 
Table V. Kappa values and the p-values of McNemar’s test for individual HPV genotypes detectable 
 by both assaysa 
 
 aThe results of 112 concordant, 36 compatible and 22 discordant samples after initial analysis are shown  
 bCI; confidence interval  
 Strength of agreement considered: **perfect, *very good, $good, +moderate 
 
Discrepancy analysis 
The compatible (n=36) and discordant (n=22) samples were reanalysed using the two genotyping 
assays in a discrepancy analysis. DNA was re-extracted from these 58 compatible/discordant 
samples. As interassay test controls 11 previously concordant (6 single and 5 multiple infections) and 
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6 previously double negative samples (LiPA X-type and LA negative) were also included, these 
samples were used for method performance assessment only. All 6 double negative samples 
remained negative and all 11 concordant samples appeared identical in both second genotyping 
assays. These internal controls were not further considered in the discrepancy analysis. Of the 58 
discrepant samples 10 were β-globin negative in LINEAR ARRAY and were also negative by LiPA. Of 
these 10 samples, 6 had been concordant and 4 had been discordant; these 10 samples were 
excluded from the discrepancy analysis. The crude initial and discrepancy analysis results of the 
remaining 48 samples are shown in Table VIa and VIb. Of the 30 compatible samples from the initial 
analysis 18 remained compatible after discrepancy analysis, while 8 appeared concordant and 4 
discordant in a comparison of the second genotyping assays. Of the 18 discordant samples from the 
first test run, 9 remained discordant in the second analyses between LiPA and LA, whereas 4 
appeared genotype concordant and 5 were concordant as LiPA X-type, LA negative. Thus, comparing 
the second LiPA and LA test, yielded 17 concordant, 18 compatible and 13 discordant results.  
Intra-assay comparisons taking these 48 samples and the 17 control samples in both initial and 
discrepancy analysis into account, show highly comparable results for both assays (Table VII). 
In conclusion, of the 160 samples considered for final analysis 80.6% (129/160) showed identical 
results, 11.2% (18/160) appeared compatible and 13 samples (8.2%) were discordant.  
 
Discussion 
Based on this study, we can conclude that the SPF10-INNO-LiPA and the LINEAR ARRAY HPV 
genotyping assays are highly congruent for the genotypes detectable in both assays. Moreover, 
manageability of both the SPF10-INNO-LiPA and the LINEAR ARRAY assay is highly comparable, as 
is to a large extent the total runtime required for both assays, including amplification and preparation 
of all of the reagents.  
Generally, a separate screening is needed preceding genotyping in order to assess a sample’s HPV 
DNA positivity, i.e., an HPV plus/minus screening. An advantage of the LiPA is the usage of the same 
amplicon for both detection of 43 different lr-, probable hr-, and hr-HPV genotypes and genotyping of 
25 different HPVs. For the LA, a pre-screening test with the PGMY primers is available using a generic 
HPV probe labelled with digoxigenin in a microtiter plate-based assay as recently described.20 Without 
the need for further amplification, this amplicon can be directly used for the LINEAR ARRAY 
genotyping assay. However, the efficiency of such a combination has not been studied. The recently 
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launched HPV Roche AMPLICOR test for HPV plus/minus screening is not meant for a LA screen. It 
could also be used as pre-test, but the assay only detects high-risk HPV types.10  
 
HPV genotype (initial analysis) HPV genotype (discrepancy analysis)Initial 
comparison LiPA_1 LA_1 
Discrepancy 
comparison LiPA_2 LA_2 
Compatible 35 33,35 Concordant 33,35 33 35 
Compatible 51 16,39,51 Concordant 51 51 
Compatible 18,33 18,31,33 Concordant 18,33 18,33 
Compatible 33 16,33 Concordant 33 33 
Compatible 68/73 58,73 Concordant 68/73 73 
Compatible 39 16,39 Concordant 39 39 
Compatible 52,53 52,53,54,67 Concordant 52,53,54 52,53,54,67 
Compatible 35,39,70 16,35,39,70,81 Concordant 35,39,70 35 39,70,84 
Compatible 16 16,59 Compatible 16 16,59 
Compatible 6,51 6,16,18,39,51,66 Compatible 6 6,16,18,39,51,66 
Compatible 51,52,53,59 45,51,52,53,59,IS39 Compatible 53 42,51,52,53,59,IS39 
Compatible 6,33 6,33,58,59,72 Compatible 6,31,33,58,59 6,33,58,59,72 
Compatible 6,16,52 6,16,42,52 Compatible 6 16,52 6,16,42,52 
Compatible 52 16,52 Compatible 6,16,52,56 16,52 
Compatible 6 6,59 Compatible 6 6,59 
Compatible 31,70 31,54,62,70 Compatible 6,31,70 62,70 
Compatible 54 54,73 Compatible 54 54,73 
Compatible 16 11,16,59,81 Compatible 16 11,16,59,81 
Compatible 56,66,68/73 39,52,56,66,68 Compatible 56,66,68/73 52,56,66,68 
Compatible 16,52 16,52,54 Compatible 16,52 16 
Compatible 53 42,53,IS39 Compatible 53 42,51,53,59,IS39 
Compatible 53,66 16,53,66 Compatible 66 53,66 
Compatible 31,33,53 33,42,45,53,54,59,61,83 Compatible 31 33,45,53,59 33,42,45,53,54 59,61,83 
Compatible 56 58 54,56,58,62 Compatible 56,58 54,56,58,62 
Compatible 54,56 54 Compatible 54,56 54 
Compatible 16,31,53,58 16,18,53,54,62,CP6108 Compatible 16,18,31,53,58 16,53,54,58,62,CP6108 
Compatible 33 33,54 Discordant 33 54 
Compatible 56,66 66,67 Discordant 56,66 67 
Compatible 56,59 59 Discordant X-type 59 
Compatible 51,53 51,53,54,62 Discordant 51,53 62 
 
Table VIa. All genotyping and comparison results of the initially compatible and discordant samples 
     assessed discrepancy analysis (see also table VIb) 
 
In the initial comparison, i.e., prior to the discrepancy analysis, LiPA did not detect 27 high-risk 
genotypes in 30 compatible cases. Evidently, all the cases involved were multiple infections, i.e., 
containing two or more HPV types. Apparently, if an infection encompasses multiple genotypes the 
SPF10-INNO-LiPA assay is less sensitive than the LA. After finding analogous results using the LiPA 
assay, Van Doorn, et al. propounded the idea of PCR competition between genotypes in mixed 
infections and suggested a combined testing algorithm using broad-spectrum and type-specific PCRs 
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for HPV 16 and HPV 18 (L.J. van Doorn, A.C. Molijn, B. Kleter, W.G.V. Quint and B. Colau, Abstr. 22nd 
IPV Conference., abstr. N-01, 2005). The complexity of assessing multiple genotypes was addressed 
previously.21 Amplification and identification of two genotypes present in equimolar amounts are likely 
possible. However, ‘primer competition’ between genotypes might occur in case one particular 
genotype is present in molar excess, out competing the other one.21 In the present study this is 
demonstrated by the samples harbouring multiple infections which were not identically genotyped by 
both assays. Also, LA detected hr-HPV 16 in 7 samples that were LiPA HPV 16 negative; after the 
second LA, however, 5 samples no longer showed HPV 16. Moreover, in a previous study Van Doorn 
and colleagues detected HPV 16 and HPV 18 using type-specific PCR in samples negative to these 
genotypes (but not for other genotypes) using general primer sets.21 In the present study we observed 
similar results (data not shown). Although viral load was not determined in the present study, low-
copy-number samples have previously shown more discrepancy in intralaboratory and interlaboratory 
comparison.22 
 
HPV genotype (initial analysis) HPV genotype (discrepancy analysis)Initial 
comparison LiPA_1 LA_1 
Discrepancy 
comparison LiPA_2 LA_2 
Discordant 6 negative Concordant 6 6 
Discordant 6,53 negative Concordant 6,53 6,53 
Discordant X-type 53 Concordant X-type negative 
Discordant 16 negative Concordant 16 16 
Discordant X-type 45,61,83 Concordant 45 45,61,83 
Discordant 53 negative Concordant X-type negative 
Discordant 52 negative Concordant X-type negative 
Discordant 53 negative Concordant X-type negative 
Discordant 52 54 Concordant X-type negative 
Discordant 66 negative Discordant 66 68 
Discordant 35 negative Discordant 35 negative 
Discordant 56 negative Discordant 56 negative 
Discordant X-type 42 Discordant X-type 42 
Discordant 68/73 negative Discordant 68/73 negative 
Discordant 51,66,68/73 negative Discordant 51 negative 
Discordant X-type 56 Discordant X-type 56 
Discordant 51 negative Discordant 51 negative 
Discordant 51 negative Discordant 51 negative 
      
 
Table VIb. All genotyping and comparison results of the  initially compatible and discordant  
      samples assessed discrepancy analysis (see also table VIa) 
 
The LA assay is unable to distinguish hr-HPV 52 from other high-risk genotypes (33, 35, and 58). This 
can be inconvenient in future studies using the LINEAR ARRAY, since hr-HPV 52 is prevalent in 
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approximately 5% of the HPV-positive women with normal cytology23 and causes 2.2% of all cervical 
cancers.5 In 19 samples of the present study hr-HPV 52 positivity could not be excluded based on LA 
genotyping. However, in these cases the comparative LiPA tests did not detect this specific genotype. 
Two samples were considered LINEAR ARRAY HPV 52 positive based on the LiPA results. 
Among the 22 discordant cases, the number of hr-HPV genotypes detected by the LINEAR ARRAY 
was not higher than the number detected by LiPA. All but three of these samples were single 
infections, predominately HPV 33, HPV 51, and HPV 52. A higher inclusivity level has been observed 
for some high- and low-risk HPV genotypes, particularly hr-HPV 33 and hr-HPV 56, when the PGMY 
amplification system is used (see product insert for the CE-marked LINEAR ARRAY HPV Genotyping 
Test, European market). The inclusivity level equates to the lowest concentration (copies/mL) that 
shows a 100% positive hit rate in a replicate of 6 tests or the concentration that is the probit predicted 
95% positive hit rate. This could explain some of the differences between the two assays observed in 
our study. Thus the LA seems to be less sensitive than the LiPA if a sample has a single infection with 
some specific HPV genotypes that are poorly amplified by PGMY. Even though the majority of 
samples was cytologically classified as normal, proper HPV assessment, including genotyping, 
remains essential particularly in healthy women with normal cytology10, especially since Wallin and 
colleagues observed a strong concordance between the HPV type found in baseline smear with 
normal cytology and the eventual type found in histological samples of invasive cancers.24 In the 
present study hr-HPV 51 was missed by LA in 4 of the discordant cases; this genotype accounted for 
approximately 0.9% of all squamous-cell cervical cancer in previous studies.5 Curiously, the 
inclusitivity level for HPV 51 is lower than the level for HPV 16 using PGMY primers, suggesting a 
highly sensitive detection (see product insert CE-marked LINEAR ARRAY HPV Genotyping Test 
European market). The observed difference in HPV 51 detection between the two assays cannot be 
explained by a lower efficiency of LINEAR ARRAY PGMY primer.  
After discrepancy analysis of the compatible and discordant cases, both LiPA and LA detected more 
concordance (Table VIa and VIb). Some previously undetected genotypes for example appeared in 
the second test run, and vice versa. This could be due to low copy numbers or sampling, as DNA re-
extracts were used for the analysis. Also it could possibly indicate the suggested competition between 
genotypes present in more or lesser molar excess. However, results from a discrepancy analysis 
should generally be handled with care and interpreted carefully. Discrepancy analyses are not perfect, 
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since an analysis is easily biased in favour of the new test, and hard and fast rules do not exist.25 
Moreover, the interpretation of results that cannot be dichotomised (i.e. concordant, compatible and 
discordant) is less straightforward.  
 
Test compareda 
Concordant
(No.) 
Compatible 
(No.) 
Discordant 
(No.) 
Total 
1st LiPA vs 2nd LiPA 48 11 6 65 
1st LA vs 2nd LA 43 16 6 65 
 
Table VII. Intra-assay comparison overview of the 65 samples re-analysed in the discrepancy 
    analysis, including the 17 control samples concordant in all four assays 
 
  a1st: initial comparison; 2nd: discrepancy comparison 
 
Failing to detect genotypes will lead to underestimation of the prevalence of certain genotypes and 
causing false-negative results. Studies concerning (i) epidemiology of HPV, (ii) HPV 
vaccination/surgical treatment trials, and (iii) cervical cancer screening and triage, especially will be 
negatively affected by this. In epidemiologic studies genotyping is compulsory in order to evaluate 
type-specific HPV DNA prevalence among infected women26, to assess geographic heterogeneity in 
HPV type distribution23 and to study type-specific HPV concordance between sexual partners.27 The 
importance of suitable algorithms for HPV detection and genotyping in addition to the introduction of 
type-specific antiviral therapies or monovalent vaccines, was already addressed by Koutsky and 
colleagues.28 Moreover, current extensive trials testing multivalent vaccines, comprising multiple 
commonly occurring HPV types, demand accurate, unequivocal, and sensitive methods and 
algorithms detecting and specifically genotyping HPV.28-30 These algorithms are also compulsory for 
clinical trials monitoring surgical treatment of HPV induced CIN lesions13, 31 or monitoring of persistent 
infections in consecutive smears, because persistence has been identified as important risk factor.32, 33 
Finally, according to Snijders and colleagues, adding general hr-HPV testing could be beneficial for 
the efficacy of the population based screening programmes for cervical cancer.9 Castle and 
colleagues however observed that ASCUS women infected with the hr-HPV 16 had a 2-year 
cumulative absolute risk for developing ≥ CIN3 of 32.5% compared to the 8.4% risk developing ≥ CIN3 
for other high-risk HPV types.14 This underlines the potential importance of assessing the specific 
genotype causing the HPV infection. Triaging patients using cytology and genotyping assays might 
have a cost benefit over cytology combined with hr-HPV testing alone. The existence of triage 
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management of ASCUS women in the United States solely depends on an accurate genotyping test.34 
Both tests assessed in the present study could be suitable as triage test. 
In addition to accurate genotyping, the appropriate detection of multiple infections seems to be an 
important application of tests when they are implemented into any format of population based 
screening for the prevention of cervical cancer, especially since the presence of multiple human 
papillomavirus genotypes in a single sample -suggesting repetitive exposure- is suspected to be 
associated with an increased risk for progressive disease.35 Moreover, mixed infections appear to be 
more frequent than previously expected; 35% of the HPV-positive samples and more than 50% of 
human immunodeficiency virus-positive women are infected with multiple HPV types.36,37 Multiple 
infections were less prevalent in cervical carcinomas.15 
In conclusion, both genotyping assays are handled equally well and have shown to be highly 
comparable. All of the HPV genotypes detected in either one or both of the assays, regardless the 
analytical or clinical sensitivity and specificity of the tests, should not be trivialized, since their natural 
behaviours and cancerous potentials in both single and mixed infections remain ambiguous.  
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General Discussion 
Since the recognition of precursor lesions in cervical cells, well organized population-based cervical 
cancer screening programmes have resulted in a significant decrease of the most common type of 
cervical cancer, squamous-cell carcinoma (SCC).1,2 Unfortunately, despite cervical screening 
programmes, a number of studies have reported a relative and/or absolute increasing incidence of the 
rarer cervical adenocarcinoma (AC), especially in young women.3-5 Early reports from the 1950s and 
1960s demonstrated that adenocarcinoma accounted for only 5% of cervical cancer cases6,7 whereas 
global estimates indicate that cervical adenocarcinomas now constitute up to 25% of cervical 
carcinomas in some western countries.8  
As squamous-cell carcinoma and its precursor lesions are far more common than glandular pre-
invasive and invasive disease, the majority of research has focussed on HPV and its relation with 
cervical squamous-cell lesions. Recently, a pooled data analysis on the risk factors of developing 
cervical adenocarcinomas has confirmed the concept of an etiological association with high-risk HPV, 
almost analogous to the established model for cervical squamous-cell carcinoma, although differences 
in patterns of type-specific high-risk HPV types were found.9 Cervical infections with HPV 16, the most 
common high-risk HPV genotype, confer a preferential risk to develop squamous-cell carcinoma, while 
infections with HPV 18 are related to an increased risk to develop adenocarcinoma.9,10  
Because of the limited success of cytological screening programmes in reducing adenocarcinomas 
and the leading role HPV 18 seems to play in the development of these lesions, the studies in this 
thesis are mainly focussed on refining the understanding of the natural behaviour of this specific HPV 
genotype.  
 
1. HPV 18 and the endocervical canal 
Glandular lesions are frequently missed by cytology due to sampling and interpretative errors. Over 
the last decades, Pap test sampling techniques have changed significantly, largely with the addition of 
sampling devices, developed to improve sampling of columnar cells. Several studies proposed 
potential benefits of improved sampling with the use of endocervical brushes and consequently, better 
identification of precursor lesions, thus reducing progression to invasive disease.11,12 Colposcopic 
assessment of these glandular lesions is rather difficult because lesions are often localized beyond the 
range of colposcopic visualization. 
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It has been postulated that high-risk HPV testing can be of additional value to detect glandular 
lesions.13,14 Most current HPV screening protocols identify the presence of one of a pool of high-risk 
HPV types, but do not identify the individual genotype. However, because a strong concordance exists 
between the type of HPV found in the baseline smear, before the development of cervical carcinoma, 
and the HPV type found in the biopsy specimen of the invasive cancer15, identification of individual 
HPV genotypes is important in cervical screening and triage to classify patients with a low or a high-
risk of developing cervical invasive disease. 
HPV 18 is preferentially found in adenocarcinoma in situ in 52 to 89% of cases and in over 50% of 
cervical adenocarcinomas whereas only 10-12% of the cervical squamous-cell carcinomas are HPV 
18 positive.3,9,16 Recently it has been shown that when comparing invasive adenocarcinoma cases to 
cytologically normal controls, the odds ratio for HPV 18 is 15.0  and for HPV 16 only 1.3, suggesting a 
preferential risk of HPV 18 for adenocarcinoma.10  
As HPV 18 is the main high-risk HPV type capable of causing severe lesions arising from the 
columnar epithelial cells, located in the endocervical part of the cervix, it can be hypothesized that 
HPV 18 has a local preferential site in the endocervical canal. If this is true then cervical specimen 
collection with sampling devices, which reach the more upper layers of the endocervical canal should 
detect more HPV 18 compared to the conventional device. Indeed, as described in chapter 4, in the 
second half of the menstrual cycle, the new device detected more HPV 18 positivity than samples 
collected with a conventional device. Moreover, we found a tendency (p=0.054) towards a higher 
detection rate of HPV 18 in the second half of the menstrual cycle when cervical samples contain 
more endocervical cells (Ecc+), thus supporting the hypothesis of a local preferential site of HPV 18 in 
the endocervical canal. Bearing in mind the fact that low-grade glandular lesions are still not well-
defined and therefore difficult to recognize as such, assessment of HPV 18 in cervical cytology might 
identify women with an increased risk of glandular abnormalities and should raise the clinical 
awareness of the gynaecologist. 
An intriguing question is why HPV 18 is preferentially present in glandular lesions and probably in the 
endocervical canal? The answer might be found in receptor studies on HPV entry into epithelial cells. 
Such studies have currently been conducted in the field and, integrins, like α-6 protein complex, have 
been reported as candidate receptors for HPV entrance.17,18 Further reseach is needed to determine 
cell or tissue specific receptors for specific HPV genotypes. 
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2. HPV clearance versus viral latency 
The identification of high-risk HPV as a necessary causal factor of cervical cancer offered the 
opportunity to assess HPV in cervical smears in order to identify women at risk of developing invasive 
disease.19,20 Due to ongoing research it is now generally accepted that a persistent infection with high-
risk HPV is of key importance to the development of cervical premalignant and malignant disorders.21-
23 The term persistence has often been insecurely defined and there is no consensus yet as to how 
long a time period implies persistence. A positive high-risk HPV test on two occasions with an interval 
of 6 months to a year, is commonly regarded as persistence. However, although widely accepted, this 
definition does not concur with our knowledge of the natural course of HPV infections. Studies on the 
natural history of HPV showed that newly acquired HPV infections are usually transient with a mean 
duration of HPV presence between 6 to 12 months, thereby, in fact, classifying most HPV positive 
women as having a persistent infection.24  
Moreover, it remains to be elucidated whether persistent infections are only characterized by the 
repeated detection of HPV, or by a state of long-term latency during which the virus remains 
undetectable only to reappear later.25,26 Consequently, if the concept of latency for HPV is true, an 
HPV infection can hardly be called transient, only because we are not able to detect this latent virus. 
Latency implies that the viral genome is present but infectious virus is generally not produced except 
during intermittent episodes of reactivation as for example with herpes simplex virus. From that point 
of view, HPV infection can be divided into chronic productive infections, in which infectious virus is 
present at relatively high DNA copy numbers and can be detected by conventional methods, and into 
latent infections, in which very small foci of cells maintain the viral DNA at low copy numbers. The 
latter definition is therefore dependent upon the sensitivity of the techniques used to demonstrate 
latent infection.  
Support for the existence of a latent state of HPV comes mainly from studies on the presence of HPV 
in immune impaired individuals.27-29 It has been postulated that HPV infections are normally held in a 
sub-clinical state by functional immune systems, but can be reactivated by immunosuppressive 
conditions. HIV positive women with low CD4+ counts, e.g., have high rates of HPV infection and high 
rates of cervical lesions.30,31 Studies on the incident detection of HPV in HIV-positive women with low 
CD4+ counts showed that newly detected HPV (i.e. HPV detection in HIV-positive women with 
previously negative HPV tests) was unrelated to sexual activity during the interval since the preceding 
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test.29,32 Silverberg et al performed serial measurements of antibodies of HPV 16 in a cohort of HIV-
positive women. Using a rise in antibodies as a marker of infection, they observed that most HPV 16 
infections occurred in women who had serological or virological evidence of a prior exposure to HPV 
16 and thus were due to either reinfection or reactivation of HPV 16. Increasing rates of antibodies 
were not associated with sexual behaviour, arguing for reactivation of a latent state of HPV 16 in HIV-
positive women, especially in those with low CD4+ counts.28  
The study described in chapter 2 supports the concept of a latent state of HPV infection. We showed 
that in women without clinical disease (no or slightly abnormal cytological disorders) short-term 
fluctuations on HPV prevalence exists, even within a single menstrual cycle. Although we used a 
highly sensitive PCR-based assay we were not able to assess HPV presence in all phases of the 
menstrual cycle in HPV positive cases. Viral DNA was probably present at low copy numbers and 
fluctuated around the level of detectability (i.e. viral load threshold) of the assay used. Assessment of 
viral loads of each specific HPV genotype at different time-points in the menstrual cycle, might have 
sustained this concept. 
The study described in chapter 3 may also lend support to the concept of a latent state of HPV 
because we have demonstrated a rate of 15% newly detected HPV shortly after the LLETZ procedure. 
Although 6 different (16, 31, 39, 51, 52, 18) newly detected high-risk HPV types were found, HPV 18 
was the most frequent type found after LLETZ. Although the sexual history between the LLETZ and 
the follow up smear was not assessed, the high appearance rate of specifically HPV 18 makes it 
doubtful that the newly detected HPV infections were the result of new sexual contacts. Whether the 
detection of new HPV 18 is attributable to reactivation of viral latent infection after a surgical procedure 
or reflects a preferential localization of HPV 18 high up in the endocervical canal or a combination of 
both needs to be determined.  
 
3. Viral load and integration of HPV  
As discussed in chapter 1, the sensitivity of HPV detection methods is based on the threshold value of 
the viral load. Generally, amplification detection assays like PCR-based techniques, are highly 
sensitive (low threshold of viral load detection), in comparison with liquid hybridization tests (high 
threshold), like e.g. the Hybrid Capture® 2 test. 
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The definition of clinical and analytical sensitivity of an HPV detection test is based on the concept that 
the level of viral load is predictive for having or developing high-grade cervical disease.33 Clinically 
relevant sensitive tests are defined as tests that are able to identify women with an increased risk of 
developing cervical cancer without greatly overestimating the women who have low-grade or no 
cytological abnormalities.34 In fact, the threshold of viral load of such a test reflects the minimum level 
of viral load needed to distinguish a clinically relevant disorder from a clinically irrelevant disorder. 
However, the association of viral load and clinical disease seems to be more complex. Cross-sectional 
studies on viral load of HPV in cytological specimens have shown that a genotype-specific association 
exists between viral load and cervical preneoplasia. In squamous lesions, the viral load of HPV 16 
increases with increasing disease severity, an effect which is not seen with HPV 18.35,36 The viral load 
of HPV 18 in squamous-cell lesions increases from normal cytology to low-grade abnormalities but is 
only modestly higher among high-grade lesions and cancer compared to cytological normal scrapes.35 
A possible explanation for the discrepancy in viral load of HPV 16 and 18 in high-grade induced 
lesions is the difference in physical state of type-specific HPV in these lesions. HPV 18 is more often 
integrated in high-grade lesions compared to HPV 16 and viral integration itself might be followed by a 
decrease in viral load.37 In chapter 5 we investigated the physical status of HPV 16 and 18 in high-
grade glandular and squamous lesions. We have demonstrated that HPV 18 was preferentially 
present in an integrated form in both squamous-cell and glandular lesions, which agrees with other 
investigators.38,39 Whether the decrease in HPV 18 viral load in severe lesions is because of 
localization of HPV 18 associated cervical lesions in the endocervical canal, where thorough sampling 
is difficult and errors might occur, or whether it is the result of an increased frequency of integration of 
viral HPV 18 DNA into the host genome, can not be determined from these studies. However, whether 
the viral load of HPV 18 is low due to the first, the second or both options, a sensitive type-specific 
HPV detection assay needs to be used in order to gain a high negative clinical predictive value in case 
of screening for HPV 18 induced lesions. 
Although the understanding of HPV associated cervical cancer development is improving, the 
influence of type-specific HPV infections on the different cell-types of the cervix is poorly understood. 
Also, the factors that regulate viral chronic persistence and the events that lead to latency are areas 
that need to be addressed if our knowledge of the natural history of papillomavirus is to be advanced 
further. 
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Summary 
Chapter 1 
Cervical screening programmes for the prevention of cervical cancer have succesfully reduced the 
incidence of cervical squamous-cell carcinoma. Unfortunately, the efficacy of such programmes on the 
incidence of adenocarcinoma is considerably less and even an increase has been reported, especially 
in younger women. 
It is now well-established that high-risk HPV genotypes play a major causative role in the development 
of cervical cancer. HPV 16 and HPV 18 are the most common types found in cervical cancer and 
together they account for 70% of cervical cancers. The limited success of screening programmes in 
detecting glandular precursors, due to a lack of clinical and cytomorphologic characteristics of these 
lesions, basic research focusing on different aspects of specific HPV 18 behaviour and clinical 
appearance might add to the knowledge of the development of adenocarcinoma and its precursor 
lesions. The studies in this thesis are mainly directed to specific features of HPV 18.  
Four questions have been postulated and are addressed in this thesis: 
 
1. Is the detection of HPV influenced by short-term fluctuations in a single menstrual 
  cycle? (chapter 2)  
2. Does HPV 18 appear in cytological samples taken after large loop excision of the 
  transformation zone? (chapter 3) 
3.  Will cervical sampling with devices that reach deeper into the endocervical canal 
 reveal more endocervical cells? If more endocervical cells are found will the 
 detection rate of HPV 18 be higher? (chapter 4) 
4.  Is the physical status of HPV 16 in high-grade squamous and glandular lesions 
 different from the physical status of HPV 18 in these cervical lesions? (chapter 5) 
 
Different HPV detection assays are available with different sensitivity and specificity depending on the 
threshold value of viral load/concentration. PCR-based techniques are more sensitive than 
conventional liquid hybridization techniques. Apart from categorising the tests based on the technique 
used, current tests can be divided according to their actual purpose, i.e. high-risk HPV detection or 
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HPV genotyping. Recently a new PCR-based technique was launched onto the market and may be 
valuable for mass-screening purposes. 
Two questions have been postulated about 2 different HPV assays and are addressed in this thesis: 
1. What is the concordance of a more established (SPF10-LiPA) PCR-based assay and a 
newly developed (Roche AMPLICOR) PCR-based assay, regarding high-risk HPV 
detection? (chapter 6)  
2. What is the concordance of a more established (SPF10-LiPA) PCR-based assay and a 
newly developed (Roche Linear Array) PCR-based assay regarding HPV-genotyping? 
(chapter 7) 
 
Chapter 2 
Chapter 2 describes short-term fluctuations of HPV prevalence in a single menstrual cycle in women 
with no cervical disorders. We found a significantly higher overall prevalence of HPV at the follicular 
phase and a high cumulative prevalence. Moreover, although 20% of cases was, at least at one time-
point, HPV 18 positive, HPV 18 was not found at the luteal phase.  
It could be postulated that the physiological widening of the cervical canal at the follicular phase, 
allows more pick up of clinical material from the upper layers of the cervical canal, resulting in higher 
detection rates of HPV and specifically HPV 18. Based on the results of this study, the hypothesis, of a 
local preferential site of HPV 18 in the endocervical canal was born. 
 
Chapter 3 
Large loop excision of the cervical transformation zone (LLETZ) is a well-established treatment mode 
for high-grade cervical intraepithelial neoplasia. It has even been postulated that LLETZ is responsible 
for the elimination of the infectious agent, human papillomavirus (HPV), causing the lesion. Most 
studies on HPV detection after LLETZ have focussed on the persistence of high-risk (hr-) HPV to 
identify women at risk for residual or recurrent disease. Therefore, the appearance and significance of 
hr-HPV types newly detected after surgical treatment has not been studied extensively so far.  
We assessed the presence of hr-HPV in high-grade squamous cervical LLETZ biopsies and in the first 
follow-up smear. We found a remarkable high presence of HPV 18 (as compared to other hr-HPV 
genotypes) in the follow up smears of women, whose LLETZ biopsies were negative for HPV 18. This 
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may argue for a release or re-activation of HPV 18 from proximal layers of the cervical canal incised 
during surgery.  
Chapter 4 
Despite population-based screening programmes for the prevention of cervical cancer the incidence of 
cervical adenocarcinomas continues to increase. HPV 18 is preferentially found in adenocarcinomas 
and it has been suggested that the endocervix is the preference site for HPV 18. In this chapter a 
recently developed cervical sampling device (Cervex-Brush® Combi) was compared to the 
conventional Cervex-brush with respect to endocervical cell collection and detection rate of HPV 18. 
Cervical samples were taken consecutively with both the traditional Cervex-Brush and the new 
Cervex-Brush Combi in one session from 49 healthy women in the first and the second half of a single 
menstrual cycle. Endocervical glandular cell amounts were evaluated and the presence of HPV was 
assessed by the SPF10-Line Blot 25 assay. 
Samples taken with the Cervex-Brush Combi contained a higher mean number of endocervical cells 
compared to samples taken with the Cervex-Brush. In the second half of the menstrual cycle, a 
significant higher cellular density of endocervical cells was found in the specimens obtained by the 
Cervex-Brush Combi. Moreover, these samples showed more HPV 18 positive cases at the second 
half of the menstrual cycle compared to samples taken with the Cervex-Brush.  
The Cervex-Brush Combi yields significantly more endocervical cells per sample and in addition 
results in higher detection rate of HPV 18 in the second half of the menstrual cycle. 
The new sampling device might therefore contribute to improve detection of endocervical lesions. 
 
Chapter 5 
The exact role of high-risk human papillomavirus (HPV) in the development of cervical carcinomas is 
not fully understood but it is generally accepted that the physical status of HPV in the host cell is of key 
importance. There is considerable evidence that viral integration into the host genome could be a 
driving factor in the transformation of a premalignant lesion into a cervical carcinoma. In Chapter 5 
differences in physical status of HPV 16 and 18 in high-grade precursor lesions of squamous-cell and 
adenocarcinomas of the cervix and in lesions in which both types of high-grade lesions are present 
were studied. 
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Regardless of HPV-genotype, integration of viral DNA into the host genome is significantly more 
frequently observed in ACIS lesions than in CIN 3 lesions. This possibly reflects intrinsic properties of 
endocervical cell types, but may also reflect a different malignant potential of ACIS in comparison to 
CIN 3 lesions.  
 
Chapter 6 
Certain types of human papillomavirus (HPV; high-risk types) are a necessary cause of the 
development of cervical disorders. Women with persistent high-risk HPV infections have an increased 
risk of developing high-grade cervical lesions, compared with those who have low-risk HPV infections 
or no HPV infection. Therefore, implementation of HPV detection into cervical screening programs for 
the prevention of cervical cancer might identify women at risk of cervical cancer. Several HPV 
detection methods with different sensitivities and specificities are available. Recently, a new PCR-
based technique, the Roche AMPLICOR® HPV Test, was developed. The current study was 
undertaken to compare HPV detection in 597 cervical scrapes, obtained from women participating in 
the national cervical screening program, using the AMPLICOR HPV Test and another PCR-based 
HPV detection method, the SPF10-LiPA system version 1. Human β-globin was not detected in nine 
specimens, which were therefore excluded from the comparison. Both tests gave a similar result in 
574/588 cases, showing an absolute agreement of 96% with a Cohen’s kappa of 0.946, indicating 
almost complete similarity of the two tests. The AMPLICOR HPV Test was sensitive, specific, feasible 
and easy to handle, which makes it, in principle, accessible for routine clinical practice and research 
applications.  
 
Chapter 7 
Accurate genotyping of human papillomavirus (HPV) is important in order to i) monitor the efficacy of 
multivalent vaccines and surgical treatment, ii) study the epidemiology of HPV infections worldwide, 
and iii) assess the oncogenic potential of high-risk HPV genotypes. Various HPV detection and 
genotyping assays have been developed to meet this demand. In chapter 7 the Roche LINEAR 
ARRAY a recently developed genotyping assay based on a well-known primer set (PGMY 09/11) is 
compared to a more established and highly sensitive genotyping assay (the SPF10-INNO-LiPA). The 
samples used for comparison showed identical results in both assays in 81% of the cases. In 11% of 
Chapter 9  Summary 
 
 126
 
the samples the tests showed comparable but not identical results, whereas in 8% no resemblance 
was observed. The differences found could be attributable to a variation in analytical sensitivity for 
certain genotypes in the assays used or to low copy numbers in particular samples. Despite the 
differences, the two assays can be regarded highly comparable and reproducible. 
 
Chapter 8 
In this chapter the hypothesis of a preferential site of HPV 18 in the endocervical canal and the 
concept of latency are discussed. A clearer understanding of both issues is important for the effective 
implementation of HPV detection in screening programmes for triage purposes and for evaluation of 
effective vaccination strategies. 
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Samenvatting 
Hoofdstuk 1 
Het bevolkingsonderzoek ter preventie van baarmoederhalskanker (cervixcarcinoom) heeft geleid tot 
een succesvolle daling in de incidentie van cervicale plaveiselcelcarcinomen. Helaas is het effect van 
van een dergelijk screeningsprogramma aanzienlijk minder voor de adenocarcinomen van de cervix 
en er zijn zelfs stijgingingen in de incidentie beschreven, in met name de jongere leeftijdsgroep. 
Het staat onomstotelijk vast dat hoog-risico HPV genotypen een causale rol spelen bij de ontwikkeling 
van cervixcarcinoom. HPV 16 en 18 zijn de meest voorkomende HPV genotypen die gevonden 
worden in baarmoederhalskanker en samen zijn zij verantwoordelijk voor 70% van de 
cervixcarcinomen. Het beperkte succes van het bevolkingsonderzoek in het ontdekken van voorlopers 
van cervicale adenocarcinomen door het ontbreken van klinische en cytomorfologische kenmerken, 
noopt tot onderzoek naar verschillende specifieke aspecten van het klinische gedrag van HPV 18. 
Dergelijk onderzoek zou wellicht kunnen bijdragen aan de kennis van de ontwikkeling van 
adenocarcinomen en haar voorlopers. De studies in dit proefschrift zijn hoofdzakelijk gericht op 
specifieke aspecten van HPV 18. 
Vier vraagstellingen zijn geformuleerd in dit proefschrift: 
1. Wordt de detectie van HPV beïnvloed door korte-termijn fluctuaties gedurende een menstruele 
cyclus? (hoofdstuk 2) 
2. Komt HPV 18 tevoorschijn in cytologische uitstrijkjes nadat er een lisexcisie van de 
transformatiezone heeft plaatsgevonden? 
3. Worden er meer endocervicale cellen gevonden in uitstrijkjes die gemaakt worden met 
borsteltjes die dieper in het cervicale kanaal reiken? Als er meer endocervicale cellen 
gevonden worden is de detectie van HPV 18 dan ook hoger? (hoofdstuk 3) 
4. Is de physical status van HPV 16 in hooggradige plaveiselcel en glandulaire afwijkingen 
verschillend van de physical status van HPV 18 in dergelijke cervicale afwijkingen? (hoofdstuk 
4) 
Er zijn meerdere HPV detectie methoden beschikbaar met verschillende sensitiviteit en 
specificiteit, afhankelijk van de drempelwaarde van de viral load/concentratie. PCR-based 
technieken zijn gevoeliger dan de conventionele liquid hybridization methoden. Naast het 
categoriseren van HPV testen op basis van de gebruikte techniek, kan men ook nog een indeling 
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maken op basis van hun eigenlijke doel, i.e. detectie van hoog-risico HPV of genotypering van 
HPV. Recent is er een nieuwe PCR-based techniek op de markt gekomen die mogelijk gebruikt 
kan worden voor het screenen van grote populaties. 
In dit proefschrift zijn de volgende twee vragen geformuleerd over 2 verschillende HPV testen: 
1. Wat is de concordantie ten aanzien van hoog-risico HPV detectie van een al langer 
bestaande PCR-based HPV test (SPF10-LiPA) en een nieuwe PCR-based HPV test (Roche 
AMPLICOR®)? (hoofdstuk 6) 
2. Wat is de concordantie ten aanzien van HPV genotypering van een al langer bestaande 
PCR-based HPV test (SPF10-LiPA) en een nieuwe PCR-based HPV test (Roche Linear 
Array)? (hoofdstuk 7) 
Hoofdstuk 2 
In hoofdstuk 2 worden bij vrouwen zonder cytologische cervicale afwijkingen, de korte-termijn 
fluctuaties van HPV prevalentie in één menstruele cyclus beschreven. We vonden een significante 
hogere overall prevalentie van HPV in de folliculaire fase en een hoge cumulatieve prevalentie. 
Bovendien werd HPV 18 nooit gedetecteerd in de luteale fase terwijl toch 20% van de vrouwen op z’n 
minst 1 keer HPV 18 positief waren. 
De physiologische verwijding van het cervicale kanaal in de folliculaire fase, zou mogelijk geleid 
kunnen hebben tot een hogere opbrengst van klinisch materiaal van de hogerop in het cervicale 
kanaal gelegen lagen met een hogere detectie van HPV in het algemeen en van HPV 18 in het 
bijzonder. Gebaseerd op de resultaten van deze studie werd de hypothese van een endocervicale 
voorkeurslokalisatie van HPV 18 geboren. 
 
Hoofdstuk 3 
De lisexcisie van de cervicale transformatiezone (LLETZ) is een veel gebruikte en beproefde methode 
om hooggradige cervicale afwijkingen te behandelen. Er wordt gesuggereerd dat LLETZ 
verantwoordelijk is voor het elimineren van het infectieuze agens, HPV. Waar de meeste studies 
hebben gekeken naar het persisteren van hoog-risico HPV na de LLETZ behandeling ten einde die 
vrouwen op te kunnen sporen die een verhoogd risico hebben op een residu of recidief van de 
afwijking, hebben wij voornamelijk het voorkomen van nieuwe HPV typen na LLETZ bestudeerd. In 
totaal werden 85 hooggradige afwijkingen (CIN laesies) en hun eerste follow up controle uitstrijkjes 
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geanalyseerd op het voorkomen van HPV. Bij 20 patienten werd hetzelfde HPV genotype gevonden in 
het LLETZ biopt en de follow up uitstrijk, terwijl bij 13 personen een nieuw HPV type werd ontdekt. 
Hierbij werd in maar liefst 8 uitstrijkjes HPV 18 gevonden. Dit opmerkelijke gegeven pleit voor het 
vrijkomen of het re-activeren van het virus uit de proximale lagen van het cervicale kanaal, 
geïncideerd tijdens de LLETZ behandeling. 
 
Hoofdstuk 4 
Ondanks het bevolkingsonderzoek ter preventie van cervixcarcinoom stijgt de incidentie van 
adenocarcinomen. HPV 18 wordt bij voorkeur gevonden in adenocarcinomen en er wordt 
gesuggereerd dat HPV een voorkeurslocalisatie heeft in de endocervix. In dit hoofdstuk wordt een 
nieuw uitstrijkborsteltje (Cervex-Brush® Combi) vergeleken met de conventionele Cervex-Brushten 
aanzien van endocervicale celopbrengst en HPV 18 detectie. 
Bij 49 vrouwen werd in de eerste en de tweede helft van de cyclus een Cervex-brush uitstrijkje 
afgenomen, onmiddellijk gevolgd door een Cervex-Brush Combi uitstrijkje. Endocervicale cellen 
werden geteld en de aanwezigheid van HPV werd getest middels de SPF10-Line Blot 25 Assay. 
De monsters die afgenomen waren met het nieuwe borsteltje bevatten een hoger gemiddeld aantal 
endocervicale cellen in vergelijking met het conventionele borsteltje. In de tweede helft van de cyclus 
werd een significant hogere endocervicale celdichtheid gevonden en meer HPV 18 positiviteit in de 
monsters van het nieuwe borsteltje in vergelijking met het conventionele borsteltje. 
Derhalve zou het nieuwe borsteltje de detectie van endocervicale afwijkingen kunnen verbeteren. 
 
Hoofdstuk 5 
De exacte rol van hoog-risico HPV in de ontwikkeling van het cervixcarcinoom is niet geheel duidelijk 
maar het is een algemeen aanvaard principe dat de physical status van HPV in het gastvrouw genoom 
een sleutelrol vervult. Er is voldoende bewijs om te suggereren dat virale integratie in het gastvrouw 
genoom een stuwende factor is in de transformatie van een premaligne naar een maligne cervicale 
afwijking. In hoofdstuk 5 wordt onderzocht of er verschillen zijn in de physical status van HPV 16 en 18 
in hooggradige voorstadia van plaveiselcel- (CIN 3) en adenocarcinomen (ACIS). 
Onafhankelijk van het HPV type, wordt er significant vaker integratie van HPV in het gastvrouw 
genoom van ACIS gevonden dan in CIN 3. Dit resultaat geeft mogelijk niet alleen de intrinsieke 
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eigenschappen van endocervicale cellen weer, maar het weerspiegelt wellicht ook een verschil in 
oncologisch potentieel van ACIS vergeleken met CIN 3. 
 
Hoofdstuk 6 
Zoals al eerder naar voren is gekomen spelen hoog-risico HPV typen een noodzakelijk rol in het 
ontstaan van cervicale afwijkingen. Vrouwen met een persisterende infectie met hoog-risico HPV 
hebben een verhoogde kans op het ontwikkelen van hooggradige cervicale afwijkingen in vergelijking 
met vrouwen met een laag-risico HPV infectie of vrouwen zonder HPV infectie. Derhalve zou 
implementatie van HPV detectie in het bevolkingsonderzoek vrouwen met een verhoogd risico op 
cervixcarcinoom kunnen opsporen. Er zijn verscheidene HPV testen verkrijgbaar met verschillende 
sensitiviteit en specificiteit. Recent is ere en nieuwe PCR-based techniek op de markt gebracht: de 
Roche AMPLICOR® HPV Test. Deze test herkent een groep van 13 hoog-risico HPV typen 
tegelijkertijd. De studie beschreven in dit hoofdstuk valideert en vergelijkt de HPV detectie in 573 
cervicale uitstrijkjes van de AMPLICOR HPV Test met de INNO-LiPA HPV detectie/genotypering test 
(SPF10-LiPA system version 1). Negen samples werden uitgesloten van de analyse omdat er geen 
humaan β-globine in kon worden aangetoond. Elf uitstrijkjes bevatten de mogelijke hoog-risico HPV 
type 53 or 66, welke niet in het spectrum van de AMPLICOR test zitten en werden dus ook uitgesloten 
van verdere analyse. 
De resulaten van de HPV detective door de Roche AMPLICOR® HPV Test  werden bevestigd door de 
INNO-LiPA HPV detectie/genotypering test in 539 van de 553 cases: Een absolute agreement van 
97.5 % met een Cohen’s kappa van 0.9327, wijzend op vrijwel identieke testen. Net als de INNO-LiPA 
HPV detectie/genotypering test bleek de AMPLICOR HPV Test sensitief, specifiek en goed 
uitvoerbaar te zijn. De waarde van de Roche AMPLICOR® HPV Test met een breed spectrum aan 
hoog-risico HPV detectie moet nog verder onderzocht worden in prospectieve klinische studies. 
 
Hoofdstuk 7 
Het correct kunnen genotyperen van het HPV is van belang ten einde 1) de doeltreffendheid te 
kunnen bepalen van multivalente vaccins en chirurgische behandelingen van CIN, 2) de 
epidemiologische verdeling van HPV over de wereld gedegen te kunnen bestuderen, en 3) het 
oncologisch potentieel van hoog-risico HPV genotypen te kunnen observeren. Diverse HPV testen zijn 
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ontwikkeld om aan deze eis te voldoen. In hoofdstuk 7 wordt de LINEAR ARRAY van Roche, een 
recent ontwikkelde genotyperingstest welke gebaseerd is op een bekende primerset (PGMY09/11) 
vergeleken met een bestaande en hooggevoelige genotyperingstest (de SPF10-INNO LiPA). Bij 81% 
van de monsters werden identieke resultaten gevonden tussen de twee testen, in 11% waren er grote, 
maar niet identieke, overeenkomsten, en in 8% werd er geen enkele overeenkomst tussen de testen 
ontdekt. De gevonden verschillen zouden kunnen worden verklaard door een variatie in analytische 
sensitiviteit voor bepaalde genotypen in een test of door een lage viral load in bepaalde monsters. 
Ondanks de gevonden verschillen kunnen de twee testen statistisch gezien worden aangemerkt als 
erg goed vergelijkbaar en reproduceerbaar. 
 
Hoofdstuk 8 
In dit hoofdstuk wordt de hypothese van een voorkeurslocalisatie van HPV 18 in het endocervicale 
kanaal en het concept van latentie bediscussieerd. Een beter begrip van beide aspecten is belangrijk 
voor een effectieve implementatie van HPV detectie in het bevolkingsonderzoek, voor triage 
doeleinden en voor de evaluatie van de effectiviteit van vaccinatie strategiëen. 
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pijler oncologie vormen we een hecht team waarin ik me prima thuis voel. 
Mijn co-promotor, dr. W. Melchers, beste Willem: 
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Mijn co-promotor, dr R. Bekkers, beste Ruud: 
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frustaties op onderzoeksgebied kwijt kon.  
Dr. H. Bulten, beste Hans, dank voor je wetenschappelijke en klinische inbreng en het filosoferen over 
het ontstaan van cervicale afwijkingen. 
Dr. A. Hopman, prof. dr. F. Ramaekers en dr. F. Smedts, beste Ton, Frans en Frank, dankzij de 
“integratie” van jullie kunde en kennis in ons HPV onderzoek werd hoofdstuk 5 een feit. Ik hoop dat we 
deze lijn in de toekomst kunnen voortzetten! 
Zonder de medewerkers van het cytologisch laboratorium en al de mensen van de sectie Moleculaire 
Microbiologie van de afdeling Medische Microbiologie en in het bijzonder Judith Bakkers en Gonneke 
Harbers hadden de data nooit verzameld en verwerkt kunnen worden. 
Mijn collegae van de subafdeling gynaecologische oncologie, Charles Schijf, Joanne de Hullu, Roy 
Kruitwagen en Petra Zusterzeel  wil ik graag bedanken voor het in mij gestelde vertrouwen en het 
overnemen van mijn klinische taken zodat ik schrijftijd kreeg om alles af te ronden.  
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Carrière maken staat of valt met een goede opvang voor de kinderen. Lieve Jolanda, zonder jou en 
jouw gezin (Rob, Mitchell en Joshua) was dit alles nauwelijks mogelijk geweest. Onze dank is niet in 
woorden uit te drukken!!  
Lieve Wien, dank voor je bijzondere vriendschap (al bijna 25 jaar!) en steun, ondanks dat je al zo lang  
in Italië woont. Heel veel dank voor het corrigeren van de manuscripten in goed leesbaar engels.  
Lieve Berty,Heidi en Natasja, dank voor jullie fijne vriendschap en het eindeloos praten over hoe lastig 
het vaak is als je en  wil werken en een gezin wil. 
Mijn paranimf Dennis van Hamont: je eigen promotie net achter de rug, een huwelijk erachteraan en 
nu toch nog tijd gevonden om aan mijn zijde te staan! Fantastisch!  
Mijn ouders wil ik ontzettend graag bedanken voor de mogelijkheden en de steun die zij mij geboden 
hebben om te worden tot wie ik nu ben. Papa, het is zo jammer dat je dit niet meer meemaakt, daarom 
draag ik met veel trots dit boekje aan jou op.  
Mijn paranimf George Tielen: mijn lieve zwager. Ik ken je al zo ongeveer mijn hele leven, was zelf 
paranimf bij jouw promotie en ben er bijzonder trots op dat je vandaag mij terzijde staat. 
Lieve Guusje, mijn allerliefste zus. De band die wij hebben is uniek en het valt niet in woorden uit te 
drukken hoe dankbaar ik ben met jouw onvoorwaardelijke steun bij alle verdrietige en blije momenten!  
Lieve Eva en Menzo, mijn ‘parttime” kinderen: wat bof ik met jullie!  
Lieve Johan, zonder jouw steun en je relativeringsvermogen was dit boekje nooit geschreven. Wat ik 
je verder wil zeggen blijft tussen ons… 
Lieve Fé en Mees, met jullie is het leven een Meesterlijk Féestje!!! 
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